Future Continuous Manufacturing and Advanced Crystallisation Research Hub

Lead Research Organisation: University of Strathclyde

Department Name: Inst of Pharmacy and Biomedical Sci

Abstract

Our Hub research is driven by the societal need to produce medicines and materials for modern living through novel manufacturing processes. The enormous value of the industries manufacturing these high value products is estimated to generate £50 billion p.a. in the UK economy. To ensure international competitiveness for this huge UK industry we must urgently create new approaches for the rapid design of these systems, controlling how molecules self-assemble into small crystals, in order to best formulate and deliver these for patient and customer. We must also develop the engineering tools, process operations and control methods to manufacture these products in a resource-efficient way, while delivering the highest quality materials.

Changing the way in which these materials are made, from what is called "batch" crystallisation (using large volume tanks) to "continuous" crystallisation (a more dynamic, "flowing" process), gives many advantages, including smaller facilities, more efficient use of expensive ingredients such as solvents, reducing energy requirements, capital investment, working capital, minimising risk and variation and, crucially, improving control over the quality and performance of the particles making them more suitable for formulation into final products. The vision is to quickly and reliably design a process to manufacture a given material into the ideal particle using an efficient continuous process, and ensure its effective delivery to the consumer. This will bring precision medicines and other highly customisable projects to market more quickly. An exemplar is the hubs exciting innovation partnership with Cancer Research UK.

Our research will develop robust design procedures for rapid development of new particulate products and innovative processes, integrate crystallisation and formulation to eliminate processing steps and develop reconfiguration strategies for flexible production. This will accelerate innovation towards redistributed manufacturing, more personalisation of products, and manufacturing closer to the patient/customer. We will develop a modular MicroFactory for integrated particle engineering, coupled with a fully integrated, computer-modelling approach to guide the design of processes and materials at molecule, particle and formulation levels. This will help optimise what we call the patient-centric supply chain and provide customisable products. We will make greater use of targeted experimental design, prediction and advanced computer simulation of new formulated materials, to control and optimise the processes to manufacture them.

Our talented team of scientists will use the outstanding capabilities in the award winning £34m CMAC National Facility at Strathclyde and across our 6 leading university spokes (Bath, Cambridge, Imperial, Leeds, Loughborough, Sheffield). This builds on existing foundations independently recognised by global industry as 'exemplary collaboration between industry, academia and government which represents the future of pharmaceutical manufacturing and supply chain R&D framework'.

Our vision will be translated from research into industry through partnership and co-investment of £31m. This includes 10 of world's largest pharmaceutical companies (eg AstraZeneca, GSK), chemicals and food companies (Syngenta, Croda, Mars) and 19 key technology companies (Siemens, 15 SMEs) Together, with innovation spokes eg Catapult (CPI) we aim to provide the UK with the most advanced, integrated capabilities to deliver continuous manufacture, leading to better materials, better value, more sustainable and flexible processes and better health and well-being for the people of the UK and worldwide. CMAC will create future competitive advantage for the UK in medicines manufacturing and chemicals sector and is strongly supported by industry / government bodies, positioning the UK as the investment location choice for future investments in research and manufacturing.

Planned Impact

The CMAC Future Manufacturing Hub team actively engage and collaborate with a wide range of research beneficiaries: leading pharmaceutical companies (e.g. AZ, GSK, Bayer, Pfizer, Lilly); companies in the process industries (e.g. Mars, AB Sugar, Syngenta, Croda); technology and supply chain companies (e.g. Siemens and 15 SMEs). It has a vibrant innovation landscape with partners including; HVM Catapult (CPI); the National Formulation Centre; medical charities (e.g. CRUK), Medicines Manufacturing Industry Partnership (MMIP) of the UK pharma manufacturing industry; Chemical Growth Partnership; International academic partners (Rutgers, Graz, Singapore) through the newly formed International Institute of Advanced Pharmaceutical Manufacturing. This strong, active and influential network of collaborators, stakeholders and business leaders (contributing £31.2m to translate the research into impact), maximises the potential to achieve the Hub vision will create substantial associated impact and benefits including:
1. Economic Impact: contributing to the UK economy by increasing the competitiveness of companies across the £50Bn Pharmaceutical and Chemicals sector. The Hub programme will impact on business innovative capacity and revenues by giving industry access to a 'particle production toolbox' which will increase competitiveness by enabling flexibility of product supply delivered through integrated multi-step continuous manufacturing processes. The Hub will accelerate development and scale up of products with improved costs, energy and material usage, delivering regeneration and economic development opportunities through creation and growth of new companies and jobs through the exploitation and commercialisation of novel processing and platform formulation technologies (potential licensing, spin-out formation) attracting direct inward R&D investment investments from global businesses.
2. Wider Societal Impacts: delivering improvements to life quality and health & wellbeing through improvements to the speed and agility of drug development, manufacture and supply required to meet current unmet customer and patient needs and future demand; availability of a wider range of effective, safe and economically viable products will impact on health across the population. Through smaller plant footprint and reduced energy consumption, continuous manufacturing will deliver lower production costs and significant positive environmental impacts. Engaging with policy-makers and influencing future regulatory frameworks will be a key activity to realise the full potential of these transformative innovations in highly regulated sectors. The manufacturing technology developments will also impact internationally - small modular reconfigurable manufacturing capability with automated, intelligent control has the potential to enable distributed manufacture with units positioned close to the point of need, tackling global priority problems; opportunities for anti-malarial or anti-retroviral products at low cost in developing economies for local distribution to patients will improve access to safe and effective healthcare.
3. Academic Impacts: an interdisciplinary approach to developing new and innovative methodologies and technologies will deliver worldwide academic opportunities in addressing the challenges facing global pharmaceutical and chemicals industries. A unique focus on manufacturing technology and connectivity across multiple stakeholders will enhance the profile of manufacturing research in key sectors of the UK economy, increasing research activity and capacity. Through training highly skilled researchers and attracting talent, a pipeline of knowledge and skilled people will be created for businesses, international collaboration, engagement and research impact (e.g. through co-authored research papers) and new opportunities for UK researchers to obtain international experience via researcher exchanges through CMACs global network.

Funded Value:

£10,864,793

Funded Period:

Jan 17 - Sep 24

Funder:

EPSRC

Project Status:

Closed

Project Category:

Research Grant

Project Reference:

EP/P006965/1

Principal Investigator:

Alastair Florence

Research Subject:

Manufacturing (70%)

Process engineering (30%)

Research Topic:

Complex fluids & soft solids (15%)

Manufact. Enterprise Ops& Mgmt (15%)

Manufacturing Machine & Plant (55%)

Particle Technology (15%)

Organisations

People	ORCID iD
Alastair Florence (Principal Investigator)
Jagjit Srai (Co-Investigator)	http://orcid.org/0000-0003-2277-2127
Brahim Benyahia (Co-Investigator)	http://orcid.org/0000-0002-5397-1498
Alison Nordon (Co-Investigator)	http://orcid.org/0000-0001-6553-8993
Cameron Brown (Co-Investigator)	http://orcid.org/0000-0001-7091-1721
Daniel Markl (Co-Investigator)	http://orcid.org/0000-0003-0411-733X
Blair Johnston (Co-Investigator)
Chris Rielly (Co-Investigator)
James Litster (Co-Investigator)
Rachel Marie Smith (Co-Investigator)	http://orcid.org/0000-0003-2340-0042
Gavin Halbert (Co-Investigator)
Claire Adjiman (Co-Investigator)	http://orcid.org/0000-0002-4573-7722
Christopher Price (Co-Investigator)
Sven Schroeder (Co-Investigator)	http://orcid.org/0000-0002-4232-5378
Joop Ter Horst (Co-Investigator)
Charles Wilson (Co-Investigator)
Jan Sefcik (Co-Investigator)
Kevin Roberts (Co-Investigator)
Andy Neely (Co-Investigator)

Publications

Author Name

Title Publication Date Published

|< < 1 2 3 4 5 6 7 8 9 10 > >|

10 25 50

Abdallah N (2022) Characterisation of inclusion complexes using powder X-ray diffraction, and low- and mid-frequency Raman spectroscopy

Adjiman C (2025) Challenges and opportunities for computer-aided molecular and process design approaches in advancing sustainable pharmaceutical manufacturing in Current Opinion in Chemical Engineering

Agimelen O (2018) Multi-sensor inline measurements of crystal size and shape distributions during high shear wet milling of crystal slurries in Advanced Powder Technology

Ahmed B (2019) Engineering of acetaminophen particle attributes using a wet milling crystallisation platform. in International journal of pharmaceutics

Ainousah BE (2017) Dual Level Statistical Investigation of Equilibrium Solubility in Simulated Fasted and Fed Intestinal Fluid. in Molecular pharmaceutics

Al-Ani A (2020) Engineering a New Access Route to Metastable Polymorphs with Electrical Confinement in Crystal Growth & Design

Al-Madhagi L (2018) X-ray Raman scattering: a new in situ probe of molecular structure during nucleation and crystallization from liquid solutions in CrystEngComm

Al-Madhagi LH (2020) Hydrophilic and hydrophobic interactions in concentrated aqueous imidazole solutions: a neutron diffraction and total X-ray scattering study. in Physical chemistry chemical physics : PCCP

Al-Sharabi M (2021) Terahertz pulsed imaging as a new method for investigating the liquid transport kinetics of a-alumina powder compacts in Chemical Engineering Research and Design

Al-Sharabi M (2020) Simultaneous investigation of the liquid transport and swelling performance during tablet disintegration. in International journal of pharmaceutics

Artistic and Creative Products
Key Findings
Impact Summary
Further Funding
Research Databases and Models
Research Tools and Methods
Collaboration
Software and Technical Products
Engagement Activities


Title	Eureka and Discovery: Dr Wei Li, Loughborough University - Lovastatin crystals
Description	Lovastatin is widely used for the treatment of hypercholesterolemia, but the crystalline form of elongated needles is notorious for its poor manufacturability of the final drug product. The aspect ratio of these needle-shaped crystals can be modified by a polymer additive, polypropylene glycol (PPG), which acts as growth blocking agent on selected crystal faces. The fastest growth path along the [100] direction is suppressed while the [010] direction indicating distinctively growth gives spindle body shape. The images show that growth from solution is disrupted on some surfaces resulting in an uneven microstructure, whilst growth on other planes remain relatively flat. Further shape modifications may be obtained using temperature cycles of crystal growth and dissolution, which overall inhibit growth along the a-axis, [100], but with minimal agglomeration and production of fines, leading to a better product for downstream formulation.
Type Of Art	Image
Year Produced	2018
Impact	The image was 2nd placed in the Eureka and Discovery category of the EPSRC Photo competition 2018.
URL	https://epsrc.ukri.org/newsevents/news/photocompetition2018winner/


Title	Medicines manufacturing toolbox
Description	Digital image representing medicines manufacturing toolbox
Type Of Art	Image
Year Produced	2021
Impact	This is part of the University of Strathclyde Images of Research exhibition which is promoted widely to general public across Scotland and especially in Glasgow.
URL	https://www.imagesofresearch.strath.ac.uk/2019/gallery.php


Title	Time-Resolved X-ray Phase-Contrast Video Imaging of Continuous Anti-Solvent Crystallisation
Description	X-ray phase-contrast video showing early crystal growth in a continuous anti-solvent crystalliser. Data was collected on the Diamond Light source I13-2 beamline. For further information see the paper: @article{das_pallipurath_leng_wanelik_mcginty_miller_kathyola_chang_al-madhagi_marathae_et al._2020, place={Cambridge}, title={Time-Resolved X-ray Phase-Contrast Imaging (XPCI) of Nucleation and Crystal Growth in the Anti-Solvent Crystallization of Lovastatin}, DOI={10.26434/chemrxiv.12911168.v1}, journal={ChemRxiv}, publisher={Cambridge Open Engage}, author={Das, Gunjan and Pallipurath, Anuradha and Leng, Joanna and Wanelik, Kazimir and McGinty, John and Miller, Russell and Kathyola, Thokozile and Chang, Sin-Yuen and Al-Madhagi, Laila H. and Marathae, Shashidhara and et al.}, year={2020}, note={This content is a preprint and has not been peer-reviewed.} }
Type Of Art	Film/Video/Animation
Year Produced	2022
URL	https://zenodo.org/record/6801295


Title	Time-Resolved X-ray Phase-Contrast Video Imaging of Continuous Anti-Solvent Crystallisation
Description	X-ray phase-contrast video showing early crystal growth in a continuous anti-solvent crystalliser. Data was collected on the Diamond Light source I13-2 beamline. For further information see the paper: @article{das_pallipurath_leng_wanelik_mcginty_miller_kathyola_chang_al-madhagi_marathae_et al._2020, place={Cambridge}, title={Time-Resolved X-ray Phase-Contrast Imaging (XPCI) of Nucleation and Crystal Growth in the Anti-Solvent Crystallization of Lovastatin}, DOI={10.26434/chemrxiv.12911168.v1}, journal={ChemRxiv}, publisher={Cambridge Open Engage}, author={Das, Gunjan and Pallipurath, Anuradha and Leng, Joanna and Wanelik, Kazimir and McGinty, John and Miller, Russell and Kathyola, Thokozile and Chang, Sin-Yuen and Al-Madhagi, Laila H. and Marathae, Shashidhara and et al.}, year={2020}, note={This content is a preprint and has not been peer-reviewed.} }
Type Of Art	Film/Video/Animation
Year Produced	2022
URL	https://zenodo.org/record/6801296


Title	Twisted Habit of Pharmaceutical Crystals
Description	This image shows twisted crystals of polymorphic form III of oxcarbazepine, a commercially available pharmaceutical drug used to treat epileptic seizures. Pharmaceutical polymorphism is the ability of drugs to exist in multiple crystalline forms that often exhibit different physical and chemical properties. Our research at Strathclyde aims to develop new approaches for controlling polymorphism, thus ensuring that medicines are always administered in the most suitable form for treating patients.
Type Of Art	Image
Year Produced	2019
Impact	This image was a category winner in the University of Strathclyde "Images of Research" competition. It was exhibited along with other category winners at a number of public venues including along the Clyde outside the Glasgow Science Centre for 1 year. The image also won 1st prize in the Crystals in Art competition at 2019 BACG


Description	The overall research programme aimed to develop more efficient approaches for developing and manufacturing medicines using science driven workflows, advanced process models and modular, flexible continuous processing MicroFactories. The work was done in two phases. Phase I Jan 2017- Q1 2021. Integrated Paracetamol Process. The CMAC Future Manufacturing Research Hub launched its research program with the development of an end-to-end process for the synthesis, purification, isolation and formulation of Paracetamol, an analgesic medicine. In Parallel a prototype digital twin was developed using PSE's gFormulate software. This short project ran from January to June 2017 and built upon the outputs of the CMAC Centre for Innovative Manufacturing (CIM). This short project assessed the current capabilities in development workflows, equipment and modelling to inform future research and it also acted as a platform for developing the new research partnership. Prototype Lovastatin MicroFactory and Digital Twin. Over the period July 2017-October 2019, CMAC developed and tested a novel prototype integrated continuous crystallisation, spherical agglomeration, filter, wash and dry process for the manufacture of Lovastatin. This is a drug where the active ingredient forms difficult to process, needle-like crystals that make the traditional manufacture process difficult and expensive. The new process can be implemented in a laboratory setting using our MicroFactory platform with the benefits of a very small space footprint. For the first time, the material from this process was successfully made into tablets using direct compression to produce an oral solid dose form with improved manufacturability. A digital twin of the new Lovastatin process has been developed. It coupled predictive models for solvent screening and selection, crystal growth, and spherical agglomeration to enable simulation of possible conditions of these integrated processes. A set of visualisation tools were developed to support the digital twin. The prototype versions of these were also demonstrated alongside the Lovastatin MicroFactory at the CMAC Open Day 2018. Research outputs from this work and the underpinning research supporting it have been added to the common outcomes as they have been disseminated (includes: Hatcher et al, Hatcher, Li et al, McGinty, Chong et al). Additional outputs include a Workflow for Spherical Agglomeration, and Population Balance Model of Spherical Agglomeration models implemented in PSE software, and validated. As part of our advanced characterisation work XPS studies of Lovastatin crystallisation, SEM of continuous antisolvent crystallisation, XPCI of Lovastatin were done to better understand the nucleation and growth mechanisms involved. A paper about this has now been accepted for publication and will be added to the database once the doi is available. The Mefenamic Acid (MFA) Digital Design and MicroFactory campaign started in December 2018 and ran until summer 2022. The early stages of the campaign looked at whether or not we could integrate the final stage of synthesis with purification and particle engineering downstream, however in the face of the impact of the COVID lockdown and challenges with equipment availability we focussed on a digital first approach to developing the particle engineering aspects of the process. The campaign built on the previous Hub research to establish a novel integrated API MicroFactory consisting of seeding vessel, crystalliser and isolation unit and an innovative Drug Product MicroFactory made up of feeder, hot melt extruder and 3D printer. The API production campaign initiated the development of a new overarching, digitally enabled workflow methodology termed Quality by Digital Design that implements predictive models alongside material sparing and rapid, small-scale experiments to extract key parameters and information to digitally design the process, understand uncertainty and global sensitivities to inform the MicroFactory test bed control strategy and operation. Extensive flowsheet modelling of end-to-end and individual unit operations provide simulations of process and operating conditions to inform how to run the continuous physical process. Primary processing test bed configuration and data structure has been set up to align with the QbDD Approach and allow for future machine learning work. The work on MFA showed how control of particle size in API material process can be achieved via the Digital First approach. The resulting powder was performance tested in vitro to verify a digital twin of the performance testing of the powder. That allowed us to develop a simple end to end digital twin that was demonstrated in the form of an Android app, at our CMAC Open Days event 16-18th May 2022. Additionally a paper about the MFA API MicroFactory was published in 2023 (https://doi.org/10.1016/j.cherd.2023.07.003). The MFA campaign progressed development of key modelling elements that had previously been gaps and addressed the operational challenges of integration across the team between modellers and experimentalists and between drug substance and drug product experts. Deviation and delays to original plan for MFA occurred due to Covid and social distancing requirements, and some refinements to the scope of the project so it matched our equipment capability. The lack of face-to-face interaction between the different groups at remote locations over such an extended period made communication and collaboration more difficult than normal, in particular for new staff during 2020-2021. Adapting to emerging challenges presented by the MicroFactory system during the campaign including the equipment and the integrated modelling framework and systems approach are covered in the MFA MicroFactory and subsequent phase II papers (see below). Secondary processing (papers by Prasad et al) showed that Rheology guided process development was successful, but also highlights the limitations of this technique. The targeted immediate release profile for the CSD of MA in Soluplus®-Sorbitol formulation has been met, whilst the stable crystalline form (I) of MFA has been retained and the consistency of drug release has been significantly improved. A novel MicroFactory prototype, combining Feeder, Hot Melt Extruder and 3D printer, has successfully produced MA tablets and a patent application has been submitted The A recent work from the Hub (Prasad, E.; Robertson, J.; Halbert, G. W. 2022) shows that formulation of MFA OSDs can be modified such that the immediate release profile is more consistent and exceeds that of commercially available tablets via use of a prototype combined Hot melt extruder and 3D printer MicroFactory platform (PG449245GB). A paper from 2023 describes a filament-free melt extrusion printer and demonstrates how it addresses the two primary drawbacks of filament-based melt extrusion 3D printing: the time and resource-intensive two-step manufacturing process, and the limited availability of pharmaceutical materials possessing suitable properties for filament-based 3D printing. It describes formulations that are not accessible via more traditional 3D printing technologies that can be accessed using the new filament -free platform and how varying the design of the tablet infill and mass impacts on the performance and ability to make patient centric dose forms. Material reconciliation showed good traceability of material during the manufacturing process. In 2021 the Hub had a successful Mid-term Review and then kicked off phase II of the Hub research as described in the 2020 CMAC Hub Annual Review and revised in the 2021-2023 CMAC Hub Annual Reviews (https://cmac.ac.uk/cmac-annual-reviews). During phase II new strands of activity were established. First, a novel crystallisation classification system was scoped and a Crystallisation Screening DataFactory was established. It includes elements to address experimental requirements in the early stage of the Quality by Digital Design workflow and is supported with new RPIF funded robotics and associated hardware. Tasks included automation and integration of the robots, and development of smart experiments using AI. In 2023-2024 the capability of the crystallisation DataFactory was expanded further to include additional advanced measurement capability and to increase the number of experiments that can be run in parallel thanks to new equipment funding from UK RPIF Round 7. The second additional activity was the WP2.3 Drug product performance modelling work that's kicked off at Sheffield and aligned with PhD and the Pressure-dependent In-Situ Monitoring of Granular Materials (EP/S02168X/1) projects. The development of these models was planned such that they can become an integrated part of the WP2.1 QbDD Workflow. In 2023 the Quality by Digital Design concept was clarified and expanded by preparing a Strategic perspective paper which is expected to be published in 2025 and mapping out version 1 of the QbDD workflows framework in more detail using the BPMN 2.0 format. This concept was shared at the CMAC Open Days 2023 QbDD speaker session and showcase. Additionally a paper that exemplifies using the QbDD workflows to deliver digitally designed API MicroFactory processes was planned with experimental work on Ibuprofen and Lamivudine exemplars taking place during 2023, and a further API completed in 2024. A paper will be published in 2025 on this piece of work. In 2024 version 2 of the QbDD workflows were mapped out and an internal report summarising what has been achieved, and mapping the gaps where further research is required was generated. Also in phase II 3 case study exemplars of digital design of API MicroFactories using the QbDD approach were completed and a paper on this was prepared. Summary of Highlighted Research Outputs At End Of Phase II QbDD Strategy The CMAC Future Manufacturing Research Hub developed the Quality by Digital Design (QbDD) approach to pharmaceutical manufacturing, building on the Quality by Design (QbD) approach introduced over 20 years ago by the FDA. The approach, benefits and necessary developments were outlined in a multi-author academic-industry paper submitted to an IJPX special edition that will be published in Q3 2025. QbDD is a strategic approach to pharmaceutical manufacturing that builds upon existing QbD principles by applying modelling and digital tools to drive key decisions in the development of new products and processes. QbDD also has the potential to enhances sustainability, efficiency, and innovation while assuring quality of the final product and accelerating the pace with which new medicines can reach patients. Crystallisation Classification System (CCS) A key element of the digital toolbox proposed in the Hub proposal was a set of predicitive tools for crystallisation, termed the CCS. The Hub team, in collaboration with our Tier 1 partners, developed a CCS User Requirement Specification (URS) under the auspices of our QbDD strategy to identify the key capabilities that this framework needs to deliver in order to address priority industry needs. CCS is one of the novel classification systems in CMAC: an integrated framework of models, experimentation and workflows, for the digital transformation of CMC development processes. The URS outlines CCS's value in medicine development, key technical deliverables, required prediction accuracy, and required data inputs. The CCS URS provided the CMAC and Hub team with a set of technical objectives to inform our research during and beyond the CMAC Hub. Indeed, the progress made and emerging research opportunities have informed subsequent research grant funding. Crystallisation Screening DataFactory (CSDF) The CSDF is a data-driven, autonomous robotic platform for optimising crystallisation process development. CSDF uses the QbDD workflow to determine what data to gather, informed by the co-created technical requirements identified in the CCS URS. It has been developed over phae II, addresssing practical materials transfer challenges using cobots, systems integration connecting automated dosing systems and reactors, as well as modelling and optimisation research to enable continuous experimentation for early crystallisation process development. The platform facilitates smart experimentation guided by exploiting machine learning. It collects Findable, Accessible, Interoperable and Reusable (FAIR) data, including 2 datasets now held in the CMAC AssetStore. Further development of this base capability to scale-out the data acquisition capability has been enabled through our RPIF Round 7 Data Lab award. QbDD Exemplar The Hub team used a QbDD workflow approach to design three API manufacturing processes. We were able to show that this approach gave 65-52% reduction in material usage and 28% reduction in experimentation compared to tranditional approaches by using digital multi-objective optimisation. A manuscript describing the research has been submitted to IJPX Special edition on QbDD to ensure effective dissemination. We have shown that QbDD improves and accelerates development pathways for this important stage of pharmaceutical manufacturing with the potential to benefit manufacturers, regulators and patients alike. Towards QbDD: MFA Process Development A paper published in 2023 by the Hub team demonstrated a holistic digital-first approach for the design and manufacture of mefenamic acid with the required quality attributes to ensure activity via oral delivery in a tablet and removing the common need for milling or other post-crystallisation processing. This digital first approach was a key step towards mapping out stages of the QbDD approach for an API enabling the design of a robust manufacturing process as well as enhancing flexibility in design space operation whilst minimising the reliance on trial-and error experimentation. Another important outcome of this work was to identify the various steps and rate processes involved in continuous crystallisation that are currently not, or poorly, modelled, providing insights to focus ongoing research in our subsequent research grants. Spherical Agglomeration The Hub team developed an enhanced mechanistic understanding and model driven workflow for the design of spherical agglomeration processes during Phase I of the project. This led to the creation of a workflow, the definition of a new critical process design parameter, the True Bridging to Solid Ratio (TBSR), which acts to simplify the choice of volume and quantity of solvents required for a successful agglomeration process. The work by the Hub team also generated a new model describing the kinetics of agglomerate formation, and a population balance model for spherical agglomeration. XPCT: Isolation - Used Time-Resolved Operando X-ray Phase Contrast Tomography (XPCT) to visualize real-time particle segregation, impurity distribution, and fluid flow during paracetamol and metacetamol isolation, optimising washing efficiency. This was an important step to monitor the dynamics of fluid flow interacting with a bed of particles exploiting Central Facilities specialised facilities for XPCT. The work has enabled better understanding of the role of material properties and process parameters on filtration processes and will inform improved predictive tools in line with our QbDD vision. X-ray Phase-Contrast Tomography: ASDs The Hub team utilised Synchrotron X-ray phase-contrast tomography (Sync-XPC-µCT) to investigate the internal microstructure of amorphous solid dispersions. This study investigated the effects of drug saturation and processing regimes on the microstructure of amorphous solid dispersions (ASDs), produced by hot melt extrusion (HME) using Sync-XPC-µCT and bespoke image analysis. The study found varying levels of heterogeneity in HME-based ASDs, linking drug saturation levels, processing conditions, and ASD microstructure. These findings challenge the assumption that HME-based ASDs are inherently homogeneous, emphasizing the need to monitor both crystallinity and microstructural properties to ensure product stability and performance. The finding is directly relevant to assuring the quality of novel medicines made using this increasingly important processing technique. Secondary Processing of Formulated Drug Products by Additive Manufacturing CMAC has developed a filament-free printer that represents a novel technology that holds the potential to significantly advance pharmaceutical additive manufacturing (Intellectual Property Office UK, patent application number 2101534.2). This has been used to explore use of this new technology to streamline processing steops involved to make oral solid dose forms. The Hub team explored manufacturability and dissolution performance of formulations of Mefenamic Acid using the novel platform where the print approach enabled variations in internal tablet microstructure to control drug release. The filament-free printer successfully printed a previously unprintable Soluplus®-based formulation, achieving targeted immediate release dissolution profiles. Feasibility Studies The hub conducted four key feasibility studies in advanced measurement & characterisation (Greenwich), anti-fouling crystalliser control (Aberdeen), 3D pharmaceutical system characterisation (Manchester), and AI-driven digital scaling-up (Sheffield). These projects allowed the Hub to engage with the wider community, highlighting orthogonal approaches to long standing challenges and identify potential new collaborations. A number of papers were published form this work and at least one collaborative grant submission generated.
Exploitation Route	The pre-competitive CMAC Future Manufacturing Research Hub programme has been co-created with our industry partners (at Sept 2024 the current ones were AstraZeneca, Chiesi, Lilly, Novartis, Pfizer, Roche, Sanofi, Takeda, UCB). The research outputs have been demonstrated at CMAC Open Days in 2018, 2020, 2022 and 2023 and Hib Showcases in Sept 2024 via live demonstrations, lab tours, talks, and posters. Research outputs were disseminated via publications, conference presentations, posters and internal reports. Learnings from this project are expected to be translated to industry partners through routes including researcher placements, CPD training, translation focused seminars, IAA and KTP projects, digital apps, and knowledge applied to proprietary industry projects run by CMAC in parallel with the Hub programme. The academic team that worked on the pre-competitive CMAC Future Manufacturing Research Hub programme will take the learnings from Phase I and II and apply them across CMAC and new and ongoing research projects. This work also linked to the research done on the aligned and now completed EPSRC ARTICULAR project (EP/R032858/1). In 2022 two new posts, funded by UKRI rapid calls, started in Q2. The Hub Impact Officer and Digital Developer have started to implement pathways to impact plans with a focus on translating digital assets and workflows both internally and across the portfolio of projects and to our Tier 1 partners. The Spherical Agglomeration workflow dissemination to partners is well progressed and the Cooling Crystallisation workflow have been disseminated to our Industry partners. A CPD course on Cooling Crystallisation is being developed and rolled out with Part one having over 20 people in CMAC and the Industry Tier1 partners "beta test" it during 2022. An AssetStore to capture CMAC Digital Assets as they are developed has been launched in 2022 with plans to utilize more extensively in 2023-2024. A plan for further dissemination and translation of the research outputs from Hub to the Tier1 partners is in place. The Quality by Digital Design Workflows that were initiated during the MFA campaign have been further developed and have been tested during the development of three more API manufacture campaigns during 2023-2024. The outputs of this work include a paper outlining the QbDD approach and opportunities in detail and has the potential to have broad impact across the Medicines Manufacturing landscape. The paper was co-authored by the academic team with 7 leading international pharmaceutical companies. The approach and methods is being further demonstrated in a second paper that exemplifies practically implementing the approach. We are currently working with our Industry Partners to ensure we are fully aligned in terms of what the QbDD Workflows develop in CMAC can deliver for Industry and focus on effective routes for translation to industry and impact. These two papers will provide a basis for further translation activity beyond formal end of the Hub. It is exciting that key findings from the Hub programme and emergent challenges identified by the team in achieving the ambitions for digital transformation and full deployment of QbDD approaches will also be developed further in subsequent funded research in particular via our EPSRC CEDAR CDT and EPSRC Mediforge: Industry 5.0 Manufacturing Hub for a Sustainable Future.
Sectors	Chemicals Digital/Communication/Information Technologies (including Software) Manufacturing including Industrial Biotechology Pharmaceuticals and Medical Biotechnology


Description	CMAC industry members over the period 2017-2024 included: Tier 1 - AstraZeneca, Bayer, Chiesi, GSK, Lilly, Novartis, Pfizer, Roche, Sanofi, Takeda, UCB; Tier 2 - Applied Materials, Altair, Anatune, Analytik, AWL, Blacktrace, Booth Welsh, Buchi, CCDC, Clairet Scientific Ltd., Dec Group, digiM, EDEM, Element Syft, Fette, Huxley Bertram, Kuka, Malvern, Medelpharm, Mettler Toledo, M-Star, Nitech, Nvidia, Pion, PwC, QbD Vision Cherrycircle, Siemens PSE, Snapdragon, Sirius Analytical, Technobis, ThermoFisher Scientific. Many of these continue to support CMAC beyond the end of this award. It is notable that we have attracted new partners (e.g. Sanofi, Lonza, Ajinomoto) during this period illustrating the international profile the centre has developed. During 2021 CMAC reached its 10-year anniversary as a result of the EPSRC Centre for Innovative Manufacturing for Continuous Manufacturing and Crystallisation (EP/I033459/1) and Future Continuous Manufacturing and Advanced Crystallisation Research Hub funding. At the celebration online event in November 2022, a forward strategy for the portfolio of projects, including and underpinned by the Hub, was published CMAC_Strategy_21-26+(6).pdf (squarespace.com). This strategy launch was aligned with a refresh of Tier 1 membership. In 2021 the Hub refreshed its ED&I policy and training and implemented a CMAC ED&I Committee with the objective to continually improve diversity and inclusion in the workplace. The Hub Phase II plan, including implementation and development of QbDD and the CCS DataFactory commenced in early 2021 and continued to end of September 2024. CMAC received a supplement of additional funds (Oct 2022-March 2023) which was used to accelerate research delivery and completion of key collaborative research papers, and to support an early career researcher training event. The project research was delivered in 2 phases and we describe the impacts for them below. Phase I was 2017-2021. Areas where we have delivered demonstrable impact from research in Phase I were: 1) Prove, demonstrate (and in some case deliver platform capabilities and equipment) new ideas and concepts that companies do not have enough time or expertise to try themselves. Predictive design exploiting model-driven workflows plus end-to-end digital twin development and concepts, MicroFactory development and operation, and advanced future supply chain concepts focused around distributed manufacturing of medicines. Progress in the award has reinforced the opportunities to support future medicines supply chains. Flexible MicroFactories now appear within the UK Medicines Manufacturing Industry Partnership (MMIP) technology and innovation roadmap. 2) Develop new workflows to efficiently and effectively develop processes and gain process understanding saving time, reducing risk and reducing resources required. The Hub developed an integrated, digitally-enabled QbDD approach that addresses the uncertainty and risks associated with robust, efficient continuous processes and extend to implementation strategies for advanced process control, and used this to deliver 3 API MicroFactory-based exemplar processes. Crucially, the capturing of the expert domain knowledge in machine readable, bpmn format allows these workflows to be automated. This is forming a key element of delivering our Lab of the Future vision enabled by the new UKRPIF Round 7 CMAC Data Lab award. There are many tools and workflows included in this approach with these developed across the academic team. These include solubility prediction tools, advanced workflows for crystallisation development including impurity rejection, drug product manufacturability via a novel Hot Melt Extruder/ 3DPrint workflow and technology. The 3DP platform has been patented and is currently progressing through the University spin-out process. 3) New measurement techniques including the use of ToF-SIMS, EXAFS, PDF, THz have been developed and applied to a range of rate processes and materials to provide new insights to structure-process-performance relationships. 4) Addressed real-time live manufacturing development challenges on commercial products delivering impacts including reduced waste, improved quality, improved reproducibility, lower costs, reduced plant down-time. [can e include something on number of NF projects as a measure of this] CMAC submitted a case study to the UK government in the 2021 Research Excellence Framework (REF) review of university research. The case study was submitted to Engineering and Allied Heath highlighting the multi-disciplinary nature of our work. The period covers 2013-2021 and really emphasises the impact of the industrially relevant research being carried out at CMAC including testimonials from industry partners outlining the impacts to date. We expect that work from 2022-2024 will be used in a future submission. In addition, work from across CMAC including the Hub contributed to the award of the Queens anniversary Prize for Excellence in Higher Education for Advanced Manufacturing to the University of Strathclyde. Now that the CMAC Hub has completed its research programme, we expect impact from Phase II, running from 2021-2024, to be generated from application of our research outputs in the wider community including our industry partners. Main research areas for expected translation and impact from the Hub in Phase II include: 1) Quality by Digital Design (QbDD) & Digital Workflows: 2 papers will be published in IJPX Special Edition on Quality by Digital Design in 2025. QbDD strategy, workflows and exemplification of the approach are covered. The publication on QbDD Strategy has been co-authored by our industry partners, and we expect both papers to be highly relevant to our partners, as well as the wider community, with potential to deliver impact there. This work helped with achieving further funding of the CERSI project that kicked off in 2025 where we aim to help regulators to use this new approach to streamline the regulatory process for new medicines. The impactful framework and ambitious vision also has informed new research and training activities through the award of an ESPRC CDT for Cyber-Physical systems for Medicines Development and Manufacturing (CEDAR) and EPSRC MediForge Manufacturing Hub for a Sustainable Future. 2) DataFactories & Model-driven Experiments: Work on crystallisation screening DataFactory (CSDF) has delivered a step change in data generation to support development of a Crystallisation Classification System (CCS) that was co-created by CMAC and our partners. The initial development and capability will be expanded in the new MediForge Hub to create end-to-end cyberphysical systems that can generate substantia new data sets to drive digital transformation of CMC. This will also help deliver Industry 5.0 goals of sustainability, resilience and human-centricity to the community. 3) Data and Digital Twins: The team has published extensively on data and digital assets developed during the Hub project. The AssetStore internal database developed in the Hub as a way of capturing developments has 33 digital assets uploaded, and 25 are from CMAC Hub work. The CMAC Industry team have recorded the number of technologies translated to industry that have delivered demonstrable impact and is working with industry to develop a sustained pipeline of translation to industry projects for the most promising tools. In March 2024 we reported to the CMAC Advisory Board that 24 assets had been translated since start of 2022 with 119 assets in portfolio. At the end of the project 126 portfolio assets had been recorded. 4) MicroFactories & Advanced Process Technology: The Hub's MSMPR platform, designed and applied across the Hub research has delivered considerable learning in the modelling, operability and optimisation of these platforms. This work will contribute to increased adoption through more robust processes. Secondary Processing filament-free printer platform developed in CMAC during the Hub project has had a patent granted and the University of Strathclyde is exploring ways to commercialise the technology. The Hub had a role to act as a National Centre throughout the project and as such has aligned with key policy. This included alignment with MMIP mission to support the UK to become a leading force in manufacturing innovation, ABPI's Manufacturing vison for the UK, The Made Smarter Report, FDA vision for Global Pharma. CMAC strategy includes aiming to achieve greater speed, quality, agility, security and sustainability, in pharmaceutical manufacturing and communicating and engaging around the need for advanced pharmaceutical manufacturing, analytics and industrial digital technology development. The need for skilled people to address the gap in Digital Transformation and Data-Driven Research has been highlighted. The UK has supported the portfolio of aligned projects underpinned by the Hub investment. The CMAC Skills pillar starts to address the requirements of the talent pipeline, and our industry partners have noted how the doctoral training at CMAC produces uniquely skilled people. Significant further funding has been awarded because of the Hub award. This has been updated in the common outcomes section and includes the awards. Recently CMAC made a presentation to Scottish Life Sciences Cross Party Working Group and Finance and Administration Committees, highlighting the high return on investment demonstrated from manufacturing research investment and advocating for further investment in medicines manufacturing research. The work in development of digital tools and autonomous lab systems for medicines development has also informed our successful CERSI bid, that will deliver pathway to impact with UK (MHRA) and international regulators (e.g. FDA) for the standardisation of assessment and evaluation frameworks for digital tools in CMC submissions. CMAC's Open Days Events have been established as a way for industry and the third sector to engage with CMAC and find out about the recent research outputs from the portfolio of projects and current capability available. Hub Director Prof Alastair Florence has been on the Organising Committee for the biannual ISCMP/ICAMM events for the duration of this award. It is an event that influences regulators and high level decision makers in the sector. Moving forward CMAC will continue to host and organise internationally important events for the Pharmaceutical Manufacturing Community. In September 2024 a one-day Showcase event was hosted in Glasgow to disseminate the Hub outputs. The main audience included a senior delegation from MMIP who toured the labs in TIC, University of Strathclyde and saw talks and a poster session with highlights from the programme. This event helped to raise awareness of the strong alignment and contribution CMAC was making through research programmes in advanced medicines manufacturing, digital transformation and sustainability initiatives. This has led to further discussions with ABPI on how best to ensure benefit from CMAC programmes can be achieved across the UK ecosystem. Our MicroFactories vision developed through the CMAC Hub has contributed to advances in the integration of process technologies, PAT and digital technologies as part of our digital first approach. In drug substance processing, this has led to advanced discussions with the MMIC to develop a pilot scale demonstrator for integrated continuous crystallisation, isolation and drying (CCID) as well as a second generation research test bed design that has been funded via our UKRPIF Data Lab. This will form a key strand in future funded programmes including EPSRC MediForge Hub and CEDAR CDT.
First Year Of Impact	2018
Sector	Chemicals,Digital/Communication/Information Technologies (including Software),Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology
Impact Types	Societal Economic


Description	ARTICULAR: ARtificial inTelligence for Integrated ICT-enabled pharmaceUticaL mAnufactuRing
Amount	£1,965,119 (GBP)
Funding ID	EP/R032858/1
Organisation	Engineering and Physical Sciences Research Council (EPSRC)
Sector	Public
Country	United Kingdom
Start	06/2018
End	06/2022


Description	Accelerated Discovery and Development of New Medicines: Prosperity Partnership for a Healthier Nation
Amount	£5,495,023 (GBP)
Funding ID	EP/S035990/1
Organisation	Engineering and Physical Sciences Research Council (EPSRC)
Sector	Public
Country	United Kingdom
Start	01/2019
End	12/2024


Description	Advanced Manufacturing Challenge Fund: SCOUT
Amount	£1,084,500 (GBP)
Organisation	Government of Scotland
Sector	Public
Country	United Kingdom
Start	03/2020
End	12/2022


Description	Application of process analytical technology (PAT) for monitoring and controlling of reactive crystallisation systems
Amount	£62,079 (GBP)
Organisation	University of Strathclyde
Sector	Academic/University
Country	United Kingdom
Start	09/2021
End	09/2024


Description	CERSI EOI - A regulatory Science Network for the Digital Transformation of Medicines Development and Manufacturing
Amount	£50,000 (GBP)
Funding ID	10113547
Organisation	Innovate UK
Sector	Public
Country	United Kingdom
Start	03/2024
End	08/2024


Description	CMMI-EPSRC - Right First Time Manufacture of Pharmaceuticals (RiFTMaP)
Amount	£1,543,632 (GBP)
Funding ID	EP/V034723/1
Organisation	Engineering and Physical Sciences Research Council (EPSRC)
Sector	Public
Country	United Kingdom
Start	08/2021
End	08/2024


Description	Computer aided solvent design to minimise solvent use in integrated synthesis, purification & isolation for sustainable pharmaceutical manufacturing
Amount	£1,351,896 (GBP)
Funding ID	EP/W01923X/1
Organisation	Engineering and Physical Sciences Research Council (EPSRC)
Sector	Public
Country	United Kingdom
Start	06/2022
End	07/2025


Description	DPN-MED: digital plug and produce network for sustainable medicines development and manufacturing
Amount	£93,472 (GBP)
Funding ID	10146161
Organisation	Innovate UK
Sector	Public
Country	United Kingdom
Start	01/2025
End	06/2025


Description	Deep Generative Models for Pharmaceutical Manufacturing Process Design
Amount	£52,573 (GBP)
Organisation	University of Strathclyde
Sector	Academic/University
Country	United Kingdom
Start	01/2021
End	12/2023


Description	Development of the next generation instrumented dissolution apparatus
Amount	£82,300 (GBP)
Funding ID	2441956
Organisation	Engineering and Physical Sciences Research Council (EPSRC)
Sector	Public
Country	United Kingdom
Start	09/2020
End	09/2024


Description	Dialling up performance for on demand manufacturing
Amount	£5,865,535 (GBP)
Funding ID	EP/W017032/1
Organisation	Engineering and Physical Sciences Research Council (EPSRC)
Sector	Public
Country	United Kingdom
Start	09/2022
End	09/2027


Description	Digital Design Accelerator Platform to Connect Active Material Design to Product Performance
Amount	£1,793,361 (GBP)
Funding ID	105811
Organisation	Innovate UK
Sector	Public
Country	United Kingdom
Start	03/2020
End	02/2022


Description	Digital Design and Manufacture of Amorphous Pharmaceuticals (DDMAP)
Amount	£1,251,700 (GBP)
Funding ID	EP/W003295/1
Organisation	Engineering and Physical Sciences Research Council (EPSRC)
Sector	Public
Country	United Kingdom
Start	02/2022
End	03/2025


Description	Digital design strategies for industrial crystallisation development: Considering active pharmaceutical ingredient properties and crystalliser hydrodynamics for process scale up
Amount	£51,293 (GBP)
Organisation	University of Strathclyde
Sector	Academic/University
Country	United Kingdom
Start	05/2020
End	05/2024


Description	Discovery and Applications of Novel Solid-State Structures: Water Bridges Salt Forms
Amount	£73,018 (GBP)
Organisation	University of Strathclyde
Sector	Academic/University
Country	United Kingdom
Start	01/2022
End	03/2025


Description	EPSRC MediForge Hub: Industry 5.0 Medicines Manufacturing Research Hub
Amount	£11,895,078 (GBP)
Funding ID	EP/Z532964/1
Organisation	Engineering and Physical Sciences Research Council (EPSRC)
Sector	Public
Country	United Kingdom
Start	05/2024
End	06/2031


Description	Enhancing virtual tablet formulation design
Amount	£83,956 (GBP)
Organisation	Engineering and Physical Sciences Research Council (EPSRC)
Sector	Public
Country	United Kingdom
Start	12/2021
End	09/2025


Description	Establishing a UK Medicines Manufacturing Innovation Centre
Amount	£13,000,000 (GBP)
Funding ID	104208
Organisation	Innovate UK
Sector	Public
Country	United Kingdom
Start	04/2018
End	12/2021


Description	Flow-Xl: A New UK Facility for Analysis of Crystallisation in Flow Systems
Amount	£1,129,049 (GBP)
Funding ID	EP/T006331/1
Organisation	Engineering and Physical Sciences Research Council (EPSRC)
Sector	Public
Country	United Kingdom
Start	03/2020
End	03/2023


Description	In situ measurements of interfacial concentration enhancement in solutions
Amount	£60,957 (GBP)
Organisation	University of Strathclyde
Sector	Academic/University
Country	United Kingdom
Start	09/2020
End	09/2023


Description	In-situ Monitoring of Flowing Pharmaceutical Powders
Amount	£95,293 (GBP)
Funding ID	2267922
Organisation	Engineering and Physical Sciences Research Council (EPSRC)
Sector	Public
Country	United Kingdom
Start	09/2019
End	09/2023


Description	Insights into surface structural dynamics for particle property control
Amount	£117,000 (GBP)
Funding ID	2595140
Organisation	Engineering and Physical Sciences Research Council (EPSRC)
Sector	Public
Country	United Kingdom
Start	08/2021
End	09/2025


Description	KTP 11937 UoStrathclyde / PSE
Amount	£136,917 (GBP)
Funding ID	KTP 11937
Organisation	Innovate UK
Sector	Public
Country	United Kingdom
Start	07/2019
End	09/2022


Description	Linking digital manufacturing to a digital tablet: Simulating tablet disintegration using discrete element and pore-scale modelling
Amount	£76,000 (GBP)
Organisation	Government of Scotland
Department	Scottish Funding Council
Sector	Public
Country	United Kingdom
Start	11/2018
End	10/2022


Description	Liquid additive layer manufacturing for pharmaceutical products
Amount	£58,374 (GBP)
Organisation	Cancer Research UK
Sector	Charity/Non Profit
Country	United Kingdom
Start	09/2019
End	09/2022


Description	Made Smarter Innovation - Digital Medicines Manufacturing Research Centre
Amount	£5,086,406 (GBP)
Funding ID	EP/V062077/1
Organisation	Engineering and Physical Sciences Research Council (EPSRC)
Sector	Public
Country	United Kingdom
Start	08/2021
End	03/2025


Description	Medicines Manufacturing Innovation Centre
Amount	£160,000 (GBP)
Funding ID	900070
Organisation	Innovate UK
Sector	Public
Country	United Kingdom
Start	04/2017
End	03/2018


Description	Modelling agglomeration and breakage during agitated vacuum thermal drying
Amount	£85,900 (GBP)
Funding ID	2267867
Organisation	Engineering and Physical Sciences Research Council (EPSRC)
Sector	Public
Country	United Kingdom
Start	09/2019
End	09/2023


Description	Modelling and AI-Driven Optimisation of Pharmaceutical Tablet Manufacturing
Amount	£62,079 (GBP)
Organisation	University of Strathclyde
Sector	Academic/University
Country	United Kingdom
Start	02/2022
End	01/2025


Description	Multi-User Facility for SAXS/WAXS Studies on Nanoscale Structures in Controlled Environments.
Amount	£1,183,496 (GBP)
Funding ID	EP/R042683/1
Organisation	Engineering and Physical Sciences Research Council (EPSRC)
Sector	Public
Country	United Kingdom
Start	05/2018
End	05/2023


Description	Novel approaches for solubility prediction based on molecular modelling and machine learning
Amount	£62,079 (GBP)
Organisation	University of Strathclyde
Sector	Academic/University
Country	United Kingdom
Start	09/2021
End	09/2024


Description	PharmaCrystNet: Improving the Predictive Capabilities of Crystallisation Models in Pharma
Amount	£153,338 (GBP)
Funding ID	EP/Z533014/1
Organisation	Engineering and Physical Sciences Research Council (EPSRC)
Sector	Public
Country	United Kingdom
Start	08/2024
End	08/2025


Description	Predicting Performance of Medicines: Disintegration and Dissolution of Pharmaceutical Tablets
Amount	£82,300 (GBP)
Funding ID	2570328
Organisation	Engineering and Physical Sciences Research Council (EPSRC)
Sector	Public
Country	United Kingdom
Start	05/2021
End	12/2024


Description	Rapid Calls: EPSRC Rapid Call funding for 2 new posts (Impact Officer & Coding Technician)
Amount	£149,919 (GBP)
Organisation	Engineering and Physical Sciences Research Council (EPSRC)
Sector	Public
Country	United Kingdom
Start	04/2021
End	12/2023


Description	Rapid, green and self-optimised additive manufacturing of medicines
Amount	£73,018 (GBP)
Organisation	University of Strathclyde
Sector	Academic/University
Country	United Kingdom
Start	09/2021
End	03/2025


Description	Real time X-ray imaging of crystallisation processes
Amount	£73,018 (GBP)
Organisation	University of Leeds
Sector	Academic/University
Country	United Kingdom
Start	09/2021
End	09/2025


Description	SHARPEN - SHARing data to accelerate Pharmaceutical manufacturing Efficiency across trusted Networks
Amount	£690,058 (GBP)
Funding ID	10106925
Organisation	Innovate UK
Sector	Public
Country	United Kingdom
Start	07/2024
End	01/2026


Description	Understanding Long-Term Stability of Solid Pharmaceutical Dosage Forms by Characterisation of the Composite Materials at Short (Nano) Scale Length Scales to Enable Modelling and Prediction of Emergent Time-Dependent Physico-Chemical Changes
Amount	£303,000 (GBP)
Funding ID	CAMS2021/IPostD/03
Organisation	Community of analytical measurement sciences
Sector	Private
Country	United Kingdom
Start	06/2021
End	06/2023


Description	Understanding the mechanisms and mitigating the undesirable effects of drying on active pharmaceutical ingredient particle properties
Amount	£59,850 (GBP)
Organisation	University of Strathclyde
Sector	Academic/University
Country	United Kingdom
Start	09/2018
End	09/2021


Description	University of Sheffield and Process Systems Enterprise Limited
Amount	£144,336 (GBP)
Funding ID	511630
Organisation	Innovate UK
Sector	Public
Country	United Kingdom
Start	03/2019
End	04/2021


Description	Using Artificial Intelligence to predict crystal structures
Amount	£38,666 (GBP)
Organisation	Cambridge Crystallographic Data Centre
Sector	Academic/University
Country	United Kingdom
Start	01/2018
End	12/2021


Title	Recirculating Liquid Jet Cell for In Situ X-ray Absorption Spectroscopy
Description	A liquid jet setup for general windowless X-ray absorption spectroscopy at beamline B18 of Diamond Light Source, UK
Type Of Material	Improvements to research infrastructure
Year Produced	2019
Provided To Others?	Yes
Impact	Enhanced use of the Diamond B18 facility for moelcular level sructure studies of liquid flowing systems


Title	CCDC 2011326: Experimental Crystal Structure Determination
Description	Related Article: Lauren E. Hatcher, Ayrton J. Burgess, Pollyanna Payne, Chick C. Wilson\|2020\|CrystEngComm\|22\|7475\|doi:10.1039/D0CE00898B
Type Of Material	Database/Collection of data
Year Produced	2020
Provided To Others?	Yes
URL	http://www.ccdc.cam.ac.uk/services/structure_request?id=doi:10.5517/ccdc.csd.cc25hyh4&sid=DataCite


Title	CCDC 2068354: Experimental Crystal Structure Determination
Description	Related Article: Lucy K. Saunders, Anuradha R. Pallipurath, Matthias J. Gutmann, Harriott Nowell, Ningjin Zhang, David R. Allan\|2021\|CrystEngComm\|23\|6180\|doi:10.1039/D1CE00355K
Type Of Material	Database/Collection of data
Year Produced	2021
Provided To Others?	Yes
URL	http://www.ccdc.cam.ac.uk/services/structure_request?id=doi:10.5517/ccdc.csd.cc27f933&sid=DataCite


Title	CCDC 2068355: Experimental Crystal Structure Determination
Description	Related Article: Lucy K. Saunders, Anuradha R. Pallipurath, Matthias J. Gutmann, Harriott Nowell, Ningjin Zhang, David R. Allan\|2021\|CrystEngComm\|23\|6180\|doi:10.1039/D1CE00355K
Type Of Material	Database/Collection of data
Year Produced	2021
Provided To Others?	Yes
URL	http://www.ccdc.cam.ac.uk/services/structure_request?id=doi:10.5517/ccdc.csd.cc27f944&sid=DataCite


Title	CCDC 2068356: Experimental Crystal Structure Determination
Description	Related Article: Lucy K. Saunders, Anuradha R. Pallipurath, Matthias J. Gutmann, Harriott Nowell, Ningjin Zhang, David R. Allan\|2021\|CrystEngComm\|23\|6180\|doi:10.1039/D1CE00355K
Type Of Material	Database/Collection of data
Year Produced	2021
Provided To Others?	Yes
URL	http://www.ccdc.cam.ac.uk/services/structure_request?id=doi:10.5517/ccdc.csd.cc27f955&sid=DataCite


Title	CCDC 2068357: Experimental Crystal Structure Determination
Description	Related Article: Lucy K. Saunders, Anuradha R. Pallipurath, Matthias J. Gutmann, Harriott Nowell, Ningjin Zhang, David R. Allan\|2021\|CrystEngComm\|23\|6180\|doi:10.1039/D1CE00355K
Type Of Material	Database/Collection of data
Year Produced	2021
Provided To Others?	Yes
URL	http://www.ccdc.cam.ac.uk/services/structure_request?id=doi:10.5517/ccdc.csd.cc27f966&sid=DataCite


Title	CCDC 2068358: Experimental Crystal Structure Determination
Description	Related Article: Lucy K. Saunders, Anuradha R. Pallipurath, Matthias J. Gutmann, Harriott Nowell, Ningjin Zhang, David R. Allan\|2021\|CrystEngComm\|23\|6180\|doi:10.1039/D1CE00355K
Type Of Material	Database/Collection of data
Year Produced	2021
Provided To Others?	Yes
URL	http://www.ccdc.cam.ac.uk/services/structure_request?id=doi:10.5517/ccdc.csd.cc27f977&sid=DataCite


Title	CCDC 2068359: Experimental Crystal Structure Determination
Description	Related Article: Lucy K. Saunders, Anuradha R. Pallipurath, Matthias J. Gutmann, Harriott Nowell, Ningjin Zhang, David R. Allan\|2021\|CrystEngComm\|23\|6180\|doi:10.1039/D1CE00355K
Type Of Material	Database/Collection of data
Year Produced	2021
Provided To Others?	Yes
URL	http://www.ccdc.cam.ac.uk/services/structure_request?id=doi:10.5517/ccdc.csd.cc27f988&sid=DataCite


Title	CCDC 2110687: Experimental Crystal Structure Determination
Description	Related Article: Weiwei Tang, Taimin Yang, Cristian A. Morales-Rivera, Xi Geng, Vijay K. Srirambhatla, Xiang Kang, Vraj P. Chauhan, Sungil Hong, Qing Tu, Alastair J. Florence, Huaping Mo, Hector A. Calderon, Christian Kisielowski, Francisco C. Robles Hernandez, Xiaodong Zou, Giannis Mpourmpakis, Jeffrey D. Rimer\|2023\|Nat.Commun.\|14\|561\|doi:10.1038/s41467-023-35924-3
Type Of Material	Database/Collection of data
Year Produced	2023
Provided To Others?	Yes
URL	http://www.ccdc.cam.ac.uk/services/structure_request?id=doi:10.5517/ccdc.csd.cc28vbp5&sid=DataCite


Title	CCDC 2121918: Experimental Crystal Structure Determination
Description	Related Article: Weiwei Tang, Taimin Yang, Cristian A. Morales-Rivera, Xi Geng, Vijay K. Srirambhatla, Xiang Kang, Vraj P. Chauhan, Sungil Hong, Qing Tu, Alastair J. Florence, Huaping Mo, Hector A. Calderon, Christian Kisielowski, Francisco C. Robles Hernandez, Xiaodong Zou, Giannis Mpourmpakis, Jeffrey D. Rimer\|2023\|Nat.Commun.\|14\|561\|doi:10.1038/s41467-023-35924-3
Type Of Material	Database/Collection of data
Year Produced	2023
Provided To Others?	Yes
URL	http://www.ccdc.cam.ac.uk/services/structure_request?id=doi:10.5517/ccdc.csd.cc2970zk&sid=DataCite


Title	CCDC 2150100: Experimental Crystal Structure Determination
Description	Related Article: Hector Polyzois, Rui Guo, Vijay K. Srirambhatla, Monika Warzecha, Elke Prasad, Alice Turner, Gavin W. Halbert, Patricia Keating, Sarah L. Price, Alastair J. Florence\|2022\|Cryst.Growth Des.\|22\|4146\|doi:10.1021/acs.cgd.2c00152
Type Of Material	Database/Collection of data
Year Produced	2022
Provided To Others?	Yes
URL	http://www.ccdc.cam.ac.uk/services/structure_request?id=doi:10.5517/ccdc.csd.cc2b5c2z&sid=DataCite


Title	CCDC 2206318: Experimental Crystal Structure Determination
Description	Related Article: Weiwei Tang, Taimin Yang, Cristian A. Morales-Rivera, Xi Geng, Vijay K. Srirambhatla, Xiang Kang, Vraj P. Chauhan, Sungil Hong, Qing Tu, Alastair J. Florence, Huaping Mo, Hector A. Calderon, Christian Kisielowski, Francisco C. Robles Hernandez, Xiaodong Zou, Giannis Mpourmpakis, Jeffrey D. Rimer\|2023\|Nat.Commun.\|14\|561\|doi:10.1038/s41467-023-35924-3
Type Of Material	Database/Collection of data
Year Produced	2023
Provided To Others?	Yes
URL	http://www.ccdc.cam.ac.uk/services/structure_request?id=doi:10.5517/ccdc.csd.cc2d1vkw&sid=DataCite


Title	CCDC 2208068: Experimental Crystal Structure Determination
Description	Related Article: A.. J. Straiton, T. A. Kathyola, C. Sweeney, J. D. Parish, E. A. Willneff, S. L. M. Schroeder, A. Morina, A. Neville, J. J. Smith, A. L. Johnson*\|2023\|ACS Appl. Eng. Mater.\|11\|2916\|doi:10.1021/acsaenm.3c00425
Type Of Material	Database/Collection of data
Year Produced	2024
Provided To Others?	Yes
URL	http://www.ccdc.cam.ac.uk/services/structure_request?id=doi:10.5517/ccdc.csd.cc2d3p07&sid=DataCite


Title	CCDC 2208069: Experimental Crystal Structure Determination
Description	Related Article: A.. J. Straiton, T. A. Kathyola, C. Sweeney, J. D. Parish, E. A. Willneff, S. L. M. Schroeder, A. Morina, A. Neville, J. J. Smith, A. L. Johnson*\|2023\|ACS Appl. Eng. Mater.\|11\|2916\|doi:10.1021/acsaenm.3c00425
Type Of Material	Database/Collection of data
Year Produced	2024
Provided To Others?	Yes
URL	http://www.ccdc.cam.ac.uk/services/structure_request?id=doi:10.5517/ccdc.csd.cc2d3p18&sid=DataCite


Title	CCDC 2217265: Experimental Crystal Structure Determination
Description	Related Article: M.W.S. Chong, S. Ottoboni, A.R.G. Martin, D. Bowering, C.J. Price, A. Nordon, I.D.H. Oswald, M.R Ward\|2022\|Acta Crystallogr.,Sect.E:Cryst.Commun.\|78\|1209\|doi:10.1107/S2056989022010647
Type Of Material	Database/Collection of data
Year Produced	2022
Provided To Others?	Yes
URL	http://www.ccdc.cam.ac.uk/services/structure_request?id=doi:10.5517/ccdc.csd.cc2df7ps&sid=DataCite


Title	Computer-aided solvent mixture design for the crystallisation and isolation of mefenamic acid
Description	The files contain the MINLP formulations presented in this publication. The MINLP problems are implemented and solved in GAMS version 28.2.0, using SBB, a local branch-&-bound MINLP solver.
Type Of Material	Database/Collection of data
Year Produced	2020
Provided To Others?	Yes
Impact	Application to pharmaceutical process development
URL	https://zenodo.org/record/3628747


Title	Data for: "A micro-XRT Image Analysis and Machine Learning Methodology for the Characterisation of Multi-Particulate Capsule Formulations"
Description	This is a collection of data and methodologies used in the following publication. Public access to the dataset is currently under embargo until 01/01/2022, as data forms part of ongoing research. Expressions of interest can be made via the contact email: researchdataproject@strath.ac.uk. Further details on the data can be found in the README file provided. Title: A micro-XRT Image Analysis and Machine Learning Methodology for the Characterisation of Multi-Particulate Capsule Formulations Authors: Frederik J. S. Doerr and Alastair J. Florence Journal: International Journal of Pharmaceutics Accepted Date: 18/11/2019 DOI: https://doi.org/10.1016/j.ijpx.2020.100041 Abstract: The application of X-ray microtomography for quantitative structural analysis of pharmaceutical multi-particulate systems was demonstrated for commercial capsules, each containing approximately 300 formulated ibuprofen pellets. The implementation of a marker-supported watershed transformation enabled the reliable segmentation of the pellet population for the 3D analysis of individual pellets. Isolated translation- and rotation-invariant object cross-sections expanded the applicability to additional 2D image analysis techniques. The full structural characterisation gave access to over 200 features quantifying aspects of the pellets' size, shape, porosity, surface and orientation. The extracted features were assessed using a ReliefF feature selection method and a supervised Support Vector Machine learning algorithm to build a model for the detection of broken pellets within each capsule. Data of three features from distinct structure-related categories were used to build classification models with an accuracy of more than 99.55% and a minimum precision of 86.20% validated with a test dataset of 886 pellets. This approach to extract quantitative information on particle quality attributes combined with advanced data analysis strategies has clear potential to directly inform manufacturing processes, accelerating development and optimisation.
Type Of Material	Database/Collection of data
Year Produced	2019
Provided To Others?	Yes
URL	https://pureportal.strath.ac.uk/en/datasets/e5d22969-77d4-46a8-83b8-818b50d8ff45


Title	Data for: "Conundrum of gamma glycine nucleation revisited: to stir or not to stir"
Description	Raw data for the paper is available as a zip file. The raw characterisation data for polymorphic identification for crystals is available as: • Fourier-transform infrared spectroscopy (FT-IR): raw spectra data as text file (.txt) and experimental results summarized in a pdf file (.pdf). • X-Ray Powder Diffraction (XRPD): raw spectra data as text file (.raw) and processed spectra data as text file (.xy). and crystal morphology data is available as: • Optical microscopic images: image files (.jpg). • Pictures of the vials: image files (.jpg) The data corresponds to the different setups and cooling temperatures presented in Figure 5 of the paper (see Figure 5.pdf). The figure has 8 parts, each with 6 concentrations. The directory structure is as follows: • Figure 5X-Setup [1/2][a/b] o YYYgGlycine-kgWater ? Morphology • Vial (AAA).jpg • Optical microscopy-sample AAA-X.JPG ? Polymorphic identification • FTIR o Sample AAA.txt o Summary.pdf • XRPD o AAA.raw o AAA.xy for example: Figure 5g-Setup 2a > 450gGlycine-kgWater > Polymorphic identification > FTIR > Sample 66G.txt The data from quenched experiments presented in SI Figure 2 in the Supplementary Information (see SI Figure 2.pdf) is also available under: SI Figure 2-Setup 1c > YYYgGlycine-kgWater > Polymorphic identification > FTIR > Sample AAA.txt
Type Of Material	Database/Collection of data
Year Produced	2019
Provided To Others?	Yes


Title	Data for: "Crystal structure of a copper-mefenamate complex solvated with diglyme and water"
Description	Raw and processed crystallographic data associated with publication: Raw data in AB4576_1_6F_100K.zip Processed data in processed.zip Further details in README.txt
Type Of Material	Database/Collection of data
Year Produced	2022
Provided To Others?	Yes
URL	https://pureportal.strath.ac.uk/en/datasets/39f97ad1-8173-4999-b0b6-41c6ae923fe6


Title	Data for: "Data mining crystallization kinetics"
Description	This is the dataset associated with the article titled "Data mining crystallisation kinetics". Files within this dataset: Molecular descriptors employed in random forests of the compounds in the database (moe_descriptors.csv) All the data collected without pre-processing, observations whose kinetic parameters were a function of solvent or antisolvent concentration, observations whose growth was measured as volume, data adjusted according to what was explained in the article (dataset_raw.csv) All the data collected with preprocessing, observations whose kinetic parameters were a function of solvent or antisolvent concentration, observations whose growth was measured as volume, data adjusted according to what was explained in the article (dataset_preprocessed.csv) Code employed to perform cluster analysis and random forests in R (script.html)
Type Of Material	Database/Collection of data
Year Produced	2020
Provided To Others?	Yes
URL	https://pureportal.strath.ac.uk/en/datasets/8f47a175-3ac7-4791-a310-82e6652bd9f5


Title	Data for: "Degradation behavior of silk nanoparticles - enzyme responsiveness"
Description	Native and PEGylated silk nanoparticles have been developed and designed for lysosomotropic drug delivery that they ultimately traffic into lysosomes, where the low pH and lysosomal enzymes trigger payload release. Our aim was therefore to investigate degradation behaviour of native and PEGylated silk nanoparticles in protease enzymes (protease XIV and a-chymotrypsin), a cysteine protease (papain) and ex-vivo enzymes from lysosomes. All datasets for each figure provided in separate zipped folders. All measurements, equipment and software used in this study are detailed in the Readme file provided.
Type Of Material	Database/Collection of data
Year Produced	2018
Provided To Others?	Yes


Title	Data for: "Developing a batch isolation procedure and running it in an automated semi-continuous unit"
Description	Dataset related to paper Developing a batch isolation procedure and running it in an automated semi-continuous unit: AWL CFD25 case study (https://doi.org/10.1021/acs.oprd.9b00512). This data set contains two folders: AWL DOE Dec 2017 and conti run PCM 220119. In the first folder all the raw and analysed data related to the isolation process development in batch mode (DOE) are reported (related to section 3.1 of the paper). In conti run PCM 220119 instead all the raw and analysed data of the continuous run are reported (relative to section 3.2 of the paper).
Type Of Material	Database/Collection of data
Year Produced	2020
Provided To Others?	Yes
URL	https://pureportal.strath.ac.uk/en/datasets/de7fb226-49f2-4e08-83da-68ff27acbe3f


Title	Data for: "Development of a novel continuous filtration unit for pharmaceutical process development and manufacturing"
Description	Dataset related to paper Development of a novel continuous filtration unit for pharmaceutical process development and manufacturing (https://doi.org/10.1016/j.xphs.2018.07.005) and for the proceeding of the Filtech 2016 conference. This dataset comprises of one zip file which contains a number of folders containing spreadsheets, images text supporting experiments.
Type Of Material	Database/Collection of data
Year Produced	2018
Provided To Others?	Yes
URL	https://pureportal.strath.ac.uk/en/datasets/ac8c0e36-72d3-4156-9fbe-e60293e33a72


Title	Data for: "Improving consistency for a Mefenamic acid immediate release formulation"
Description	This data set supports the findings of the study 'Improving consistency for a Mefenamic acid immediate release formulation' published in the Journal of Pharmaceutical Sciences. Data is provided in Microsoft excel format. Original data files are available upon request. Particle size analysis data - Qic/PIC, dynamic imaging system, equipped with the Rhodos attachment from Sympathec Rheology: Temperature sweep and Frequency sweep data - Haake Mars III rotational rheometer Hot-melt-extrusion process data - Process 11, Thermo Fisher Filament diameter data Mechanical testing: Texture Analyser TA-XT (Stable Micro Systems) equipped with a mini 3-point bend rig HPLC data and method validation - Agilent 1100 LC system equipped with G1315A Diode Array Detector Dissolution test data: ADT8i Dissolution bath (USP I, basket) apparatus with a closed loop setting and a T70+ UV/Visible Spectrophotometer (Automated Lab Systems)
Type Of Material	Database/Collection of data
Year Produced	2020
Provided To Others?	Yes
URL	https://pureportal.strath.ac.uk/en/datasets/18916640-5b9d-4bea-afed-db2e1ca0f207


Title	Data for: "Manual versus Microfluidic-assisted Nanoparticle Manufacture: Impact of Silk Fibroin Stock on Nanoparticle Characteristics"
Description	These files contain quantitative data sets (Excel sheets) for the respective figures shown in the research paper and SI information. The particle characteristics are qualitatively assessed by scanning electron microscopy (image are JPEG and TIF formats). Technical information for the SEM images are included.
Type Of Material	Database/Collection of data
Year Produced	2020
Provided To Others?	Yes
URL	https://pureportal.strath.ac.uk/en/datasets/7387b6dc-f207-4c2f-8f97-94b3bd651468


Title	Data for: "Peptide Isolation via Spray Drying: Particle Formation, Process Design and Implementation for the Production of Spray Dried Glucagon"
Description	This is a collection of data and methodologies used in the following publication. Public access to the dataset is currently under embargo until 01/01/2021. Expressions of interest can be made via the contact email: researchdataproject@strath.ac.uk. Further details on the data can be found in the README file provided. Title: Peptide Isolation via Spray Drying: Particle Formation, Process Design and Implementation for the Production of Spray Dried Glucagon Authors: Frederik J. S. Doerr, Lee J. Burns, Becky Lee, Jeremy Hinds, Rebecca L. Davis-Harrison, Scott A. Frank, Alastair J. Florence Journal: Pharmaceutical Research Accepted Date: 28/09/2020 DOI: (tbc) Abstract: Purpose Spray drying plays an important role in the pharmaceutical industry for product development of sensitive bio-pharmaceutical formulations. Process design, implementation and optimisation require in-depth knowledge of process-product interactions. Here, an integrated approach for the rapid, early-stage spray drying process development of trehalose and glucagon on lab-scale is presented. Methods Single droplet drying experiments were used to investigate the particle formation process. Process implementation was supported using in-line process analytical technology within a data acquisition framework recording temperature, humidity, pressure and feed rate. During process implementation, off-line product characterisation provided additional information on key product properties related to residual moisture, solid state structure, particle size/morphology and peptide fibrillation/degradation. Results A psychrometric process model allowed the identification of feasible operating conditions for spray drying trehalose, achieving high yields of up to 84.67%, and significantly reduced levels of residual moisture and particle agglomeration compared to product obtained during non-optimal drying. The process was further translated to produce powders of glucagon and glucagon-trehalose formulations with yields of >83.24%. Extensive peptide aggregation or degradation was not observed. Conclusions The presented data-driven process development concept can be applied to address future isolation problems on lab-scale and facilitate a systematic implementation of spray drying for the manufacturing of sensitive bio-pharmaceutical formulations.
Type Of Material	Database/Collection of data
Year Produced	2020
Provided To Others?	Yes
URL	https://pureportal.strath.ac.uk/en/datasets/dcb859db-fe0d-4a56-b001-3f3d7ac6c44a


Title	Data for: "Quantitative Investigation of Particle Formation of a Model Pharmaceutical Formulation using Single Droplet Evaporation Experiments and X-Ray Tomography"
Description	This is a collection of data and methodologies used in the following publication. Public access to the dataset is currently under embargo, as data forms part of ongoing PhD research. Expressions of interest can be made via the contact email: researchdataproject@strath.ac.uk Title: Quantitative Investigation of Particle Formation of a Model Pharmaceutical Formulation using Single Droplet Evaporation Experiments and X-Ray Tomography Authors: Frederik J. S. Doerr, Iain D. H. Oswald, Alastair J. Florence Accepted Date: 18/09/2018 DOI: 10.1016/j.apt.2018.09.027 Abstract: The implementation of a particle design platform that can be applied to novel pharmaceutical systems using acoustic levitation (SAL) and X-ray tomography (XRT) is discussed. Acoustic levitation was employed to provide a container-less particle design environment for single droplet evaporation experiments. Dried particles were subject to further visual and quantitative structural analysis using X-ray tomography to assess the three-dimensional volume space. The workflow of the combined SAL-XRT platform has been applied to investigate the impact of increasing HPMC K100LV concentrations on the evaporation, drying and final particle morphology of particles from a model pharmaceutical formulation containing metformin and D-mannitol. The morphology and internal structure of the formulated particles after drying are dominated by a crystalline core of D-mannitol partially suppressed with increasing HPMC K100LVadditions. The final structure can be correlated to the observed evaporation kinetics. The characterisation of formulated metformin hydrochloride particles with increasing polymer content demonstrated the importance of an early-stage quantitative assessment of formulation related particle properties. The ability to study the evolution of solid phase formation and its influence on the final particle morphology can enable the selection of formulation and process parameter that deliver the desired particle structure and consequent performance by design.
Type Of Material	Database/Collection of data
Year Produced	2018
Provided To Others?	Yes


Title	Data for: "The impact of paracetamol impurities on face properties: investigating the surface of single crystals using TOF-SIMS"
Description	AFM, TOF-SIMS, LC-TOF, optical microscope, raman microscopy, single crystal x-ray, SEM, solubility and UV-vis spectrometery data of paracetamol and 4-nitrophenol single crystals and on face impurities
Type Of Material	Database/Collection of data
Year Produced	2018
Provided To Others?	Yes


Title	Data for: "Understanding effect of filtration and washing on dried product: Paracetamol case study"
Description	Dataset related to paper Understanding effect of filtration and washing on dried product: Paracetamol case study (https://doi.org/10.1016/j.powtec.2020.02.064). This data set contains three folders: filtration-washing-drying, sedimentation, wettability folders. In filtration-washing-drying you find the data related to section 4.1 (parameter affecting filtration (excluded the sedimentation part), section 4.2, section 4.3, section 4.4, section 4.5. In sedimentation folder you find data related to the filtration experiments where sedimentation of particles were occurring (pre-settling cake prior filtration or reloading filtrate on top of the cake to re-filtering it again. In folder wettability you find the Washburn experiments described in the supplementary information section. In SAM data_solubility analysis excel document a list of solubility by equilibration data are reported.
Type Of Material	Database/Collection of data
Year Produced	2020
Provided To Others?	Yes
URL	https://pureportal.strath.ac.uk/en/datasets/cce27859-8c9f-4925-96de-b32711fae0c3


Title	Data for:"Microfluidic-assisted silk nanoparticle tuning"
Description	The current manufacture of silk nanoparticles using desolvation method is time-consuming and lack ability to tune nanoparticle characteristics. Over the last decade, microfluidics has been developed which enables to manipulate particle properties by fine-tuning process parameters such as the total flow rate and flow rate ratios. Our aim was therefore to manufacture silk nanoparticles by desolvation using the NanoAssemblrTM microfluidic setup. All datasets for each figure provided in separate zipped folders. All measurements, equipment and software used in this study are detailed in the Readme file provided
Type Of Material	Database/Collection of data
Year Produced	2018
Provided To Others?	Yes


Title	Dataset for "Continuous flow for materials synthesis, assembly and crystallisation at Diamond: discovery and delivery of high value materials"
Description	Continuous crystallisation of the model system Carbamazepine (CBZ) in ethanol in the KRAIC-D (Kinetically Regulated Automated Input Crystalliser - Diffraction) platform on beamline I11 (high resolution powder diffraction) is presented. The effect of introducing a controlled solid interface into the crystallisation process is investigated, where CBZ form III seeds are introduced in polymorphic purity at different seeding positions (pre- and post-nucleation) throughout the length of the KRAIC-D. The video associated with Chapter 4 corresponds with a post-nucleation CBZ form III experiment where a separation of crystal habit is observed as a result of the different interaction with the flow paths in the solution slugs with the segmented flow. The second device is the KRAIC-S (Kinetically Regulated Automated Input Crystalliser - Single Crystal) platform installed at I19 (small molecule single crystal beamline) employed to investigate the continuous crystallisation of paracetamol (PCM) in 60:40 water:isopropanol via a range of experiments including unseeded and seeded cooling crystallisations. The unseeded experiments also looked at the crystallisation at different set points along the KRAIC-S (6.7 m and 8.7 m) to investigate crystal growth and crystal rotation at different length scales. The videos associated with Chapter 5 include single crystals produced from the range of experiments investigated. Each video tracks a different single crystal in a solution slug, where through use of the slug triggering mechanism, whereby an optical trigger prompts translation of the motorised stage to artificially suspend the single crystal in the X-ray beam during data collection. These videos complement the diffraction data and can provide explanation for data collections, which do not achieve cell indexation as the single crystal is shown to move in and out of the X-ray beam in these videos.
Type Of Material	Database/Collection of data
Year Produced	2020
Provided To Others?	Yes
URL	https://researchdata.bath.ac.uk/id/eprint/779


Title	Description of the thermodynamic properties and fluid-phase behaviour of aqueous solutions of linear, branched, and cyclic amines. AIChE J 2021
Description	All computational data for figures presented in the publication.
Type Of Material	Database/Collection of data
Year Produced	2021
Provided To Others?	Yes
Impact	Use in the modelling of complex mixtures of fluids, including in pharmaceutical process development and in CO2 capture.
URL	https://zenodo.org/record/4488482


Title	Extending the SAFT- ? Mie approach to model benzoic acid, diphenylamine, and mefenamic acid: Solubility prediction and experimental measurement
Description	All computational and measured data in the publication.
Type Of Material	Database/Collection of data
Year Produced	2021
Provided To Others?	Yes
Impact	Use in models of complex mixtures in pharmaceutics and separations
URL	https://zenodo.org/record/4700674


Title	Extending the SAFT- ? Mie approach to model benzoic acid, diphenylamine, and mefenamic acid: Solubility prediction and experimental measurement
Description	All computational and measured data in the publication.
Type Of Material	Database/Collection of data
Year Produced	2021
Provided To Others?	Yes
URL	https://zenodo.org/record/4700673


Title	Model-based solvent selection for integrated synthesis, crystallisation and isolation processes
Description	We present a systematic process-wide solvent selection tool based on computer-aided mixture/blend design (CAMbD) (Gani, 2004) for the integrated synthesis, crystallisation and isolation of pharmaceutical compounds. The method proposed simultaneously identifies the solvent and/or antisolvent mixture, mixture composition and process temperatures that optimise one or more key performance indicators. Additionally, the method entails comprehensive design specifications for the integrated process, such as the miscibility of the synthesis, crystallisation and wash solvents. The design approach is illustrated by identifying optimal solvent mixtures for the synthesis, crystallisation and isolation of mefenamic acid. Furthermore, a multi-objective CAMbD problem is formulated and shows that a mefenamic acid with purity of 98.8% can be achieved without significant loss of process performance in terms of the solvent E-factor.
Type Of Material	Database/Collection of data
Year Produced	2022
Provided To Others?	Yes
Impact	Use in the development of pharmaceutical processes. New funding secured.
URL	https://zenodo.org/record/5585546


Title	Modeling the thermodynamic properties of saturated lactones in non-ideal mixtures with the SAFT-? Mie approach. JCED 2023
Description	All computational data in the publication.
Type Of Material	Database/Collection of data
Year Produced	2023
Provided To Others?	Yes
URL	https://zenodo.org/record/8268756


Title	Modeling the thermodynamic properties of saturated lactones in non-ideal mixtures with the SAFT-? Mie approach. JCED 2023
Description	All computational data in the publication.
Type Of Material	Database/Collection of data
Year Produced	2023
Provided To Others?	Yes
URL	https://zenodo.org/record/8268755


Title	Supplementary information files for A framework for systematic crystal shape tuning - case of Lovastatin's needle-shaped crystals
Description	© the authors, CC-BY 4.0Supplementary files for article A framework for systematic crystal shape tuning - case of Lovastatin's needle-shaped crystalsOne of the most important challenges in the pharmaceutical industry is to produce crystals with desired size and shape distributions, to enhance the critical quality attributes of the drug product, such as efficacy, and to improve manufacturability during downstream processing, such as filtration, drying and granulation. The paper provides a framework for effective crystal shape and size tuning, based on a systematic exploration of standard techniques, such as the linear cooling and supersaturation control (SSC), and novel methods based on the systematic combination of several techniques, namely direct nucleation control (DNC), wet milling, SSC and shape modification additives. The crystallization of lovastatin, which is notorious for its challenging needle-shaped crystals, with an extremely high aspect ratio, was used as a case study, and polypropylene glycol (PPG-4000), at different concentrations, was used as an effective shape modifier from small-scale tests studied previously. The proposed techniques were implemented in the case of seeded and unseeded systems. It was demonstrated that the combination of temperature cycling and polymer additive enhances greatly the control over the aspect ratio and crystal size distribution, compared to conventional linear cooling and SSC strategies. The implementation of wet milling at the beginning of the process, or the introduction of seeds, enhances even further the control of the critical quality attributes of the crystalline product.
Type Of Material	Database/Collection of data
Year Produced	2024
Provided To Others?	Yes
URL	https://repository.lboro.ac.uk/articles/dataset/Supplementary_information_files_for_A_framework_for_...


Title	Supplementary information files for A framework for systematic crystal shape tuning - case of Lovastatin's needle-shaped crystals
Description	© the authors, CC-BY 4.0Supplementary files for article A framework for systematic crystal shape tuning - case of Lovastatin's needle-shaped crystalsOne of the most important challenges in the pharmaceutical industry is to produce crystals with desired size and shape distributions, to enhance the critical quality attributes of the drug product, such as efficacy, and to improve manufacturability during downstream processing, such as filtration, drying and granulation. The paper provides a framework for effective crystal shape and size tuning, based on a systematic exploration of standard techniques, such as the linear cooling and supersaturation control (SSC), and novel methods based on the systematic combination of several techniques, namely direct nucleation control (DNC), wet milling, SSC and shape modification additives. The crystallization of lovastatin, which is notorious for its challenging needle-shaped crystals, with an extremely high aspect ratio, was used as a case study, and polypropylene glycol (PPG-4000), at different concentrations, was used as an effective shape modifier from small-scale tests studied previously. The proposed techniques were implemented in the case of seeded and unseeded systems. It was demonstrated that the combination of temperature cycling and polymer additive enhances greatly the control over the aspect ratio and crystal size distribution, compared to conventional linear cooling and SSC strategies. The implementation of wet milling at the beginning of the process, or the introduction of seeds, enhances even further the control of the critical quality attributes of the crystalline product.
Type Of Material	Database/Collection of data
Year Produced	2024
Provided To Others?	Yes
URL	https://repository.lboro.ac.uk/articles/dataset/Supplementary_information_files_for_A_framework_for_...


Description	AWL are Tier 2 Members of CMAC - Hub
Organisation	Alconbury Weston Ltd
Country	United Kingdom
Sector	Private
PI Contribution	University of Strathclyde is the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution	AWL are Tier 2 members of CMAC
Impact	CMAC Future Manufacturing Research Hub works with Tier 2 Technology providers to solve specific challenges as part of the overall research programme.
Start Year	2017


Description	Analytik/Laminar
Organisation	Analytik Ltd
Country	United Kingdom
Sector	Private
PI Contribution	University of Strathclyde are the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution	Analytik/Laminar are Tier 2 members of CMAC
Impact	CMAC Future Manufacturing Research Hub works with Tier 2 Technology providers to solve specific challenges as part of the overall research programme
Start Year	2021


Description	Anatune
Organisation	Anatune
Country	United Kingdom
Sector	Private
PI Contribution	University of Strathclyde is the lead organisation of the CMAC Future Manufacturing Research Hub .
Collaborator Contribution	Anatune are Tier 2 members of CMAC
Impact	CMAC Future Manufacturing Research Hub works with Tier 2 Technology providers to solve specific challenges as part of the overall research programme.
Start Year	2020


Description	AstraZeneca - Hub Tier 1 Partner
Organisation	AstraZeneca
Department	Research and Development AstraZeneca
Country	United Kingdom
Sector	Private
PI Contribution	University of Strathclyde are the lead organisation of the CMAC Future Manufacturing Research Hub .
Collaborator Contribution	AstraZeneca are Tier 1 members of CMAC.
Impact	CMAC Future Manufacturing Research Hub governance includes Tier 1 inputs to Industry Board and Technical Committee. Tier 1s are involved in Mentor Groups and Placements for PhD students, and other researchers.
Start Year	2017


Description	AstraZeneca - Hub Tier 1 Partner
Organisation	University of Strathclyde
Country	United Kingdom
Sector	Academic/University
PI Contribution	University of Strathclyde are the lead organisation of the CMAC Future Manufacturing Research Hub .
Collaborator Contribution	AstraZeneca are Tier 1 members of CMAC.
Impact	CMAC Future Manufacturing Research Hub governance includes Tier 1 inputs to Industry Board and Technical Committee. Tier 1s are involved in Mentor Groups and Placements for PhD students, and other researchers.
Start Year	2017


Description	Bayer - Hub Tier 1 Partner
Organisation	Bayer
Country	Germany
Sector	Private
PI Contribution	University of Strathclyde are the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution	Bayer were Tier 1 members of CMAC.
Impact	CMAC Future Manufacturing Research Hub governance includes Tier 1 inputs to Industry Board and Technical Committee. Tier 1s are involved in Mentor Groups and Placements for PhD students, and other researchers.
Start Year	2017


Description	Blacktrace are Tier 2 Members of CMAC - Hub
Organisation	Blacktrace Holdings Ltd
Country	United Kingdom
Sector	Private
PI Contribution	University of Strathclyde is the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution	Blacktrace are Tier 2 members of CMAC
Impact	CMAC Future Manufacturing Research Hub works with Tier 2 Technology providers to solve specific challenges as part of the overall research programme
Start Year	2017


Description	Britest - are Tier 2 Members of CMAC - Hub
Organisation	Britest
Country	United Kingdom
Sector	Private
PI Contribution	University of Strathclyde is the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution	Britest are Tier 2 members of CMAC. They have provided training and problem solving workshops for the Hub Team.
Impact	CMAC Future Manufacturing Research Hub works with Tier 2 Technology providers to solve specific challenges as part of the overall research programme.
Start Year	2017


Description	Buchi - Tier 2 Members of CMAC - Hub
Organisation	Büchi Labortechnik
Country	Switzerland
Sector	Hospitals
PI Contribution	University of Strathclyde is the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution	Buchi were Tier 2 members of CMAC
Impact	CMAC Future Manufacturing Research Hub works with Tier 2 Technology providers to solve specific challenges as part of the overall research programme. In this case research involving the Buchi spray dryer.
Start Year	2017


Description	CCDC are Tier 2 Members of CMAC - Hub
Organisation	Cambridge Crystallographic Data Centre
Country	United Kingdom
Sector	Academic/University
PI Contribution	University of Strathclyde is the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution	CCDC are Tier 2 members of CMAC. They jointly supported a PhD aligned with Hub and assisted with delivery of the Lovastatin project by use of the CCDC reporting tools. The Hub uses the databases as part of the Quality by Digital Design approach.
Impact	CMAC Future Manufacturing Research Hub works with Tier 2 Technology providers to solve specific challenges as part of the overall research programme.
Start Year	2019


Description	Chiesi are Tier 1 Members of CMAC - Hub
Organisation	Chiesi
Country	Italy
Sector	Private
PI Contribution	University of Strathclyde are the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution	Chiesi re Tier 1 members of CMAC
Impact	CMAC Future Manufacturing Research Hub governance includes Tier 1 inputs to Industry Board and Technical Committee. Tier 1s are involved in Mentor Groups and Placements for PhD students, and other researchers.
Start Year	2021


Description	Clairet Scientific Ltd are Tier 2 Members of CMAC - Hub
Organisation	Clairet Scientific
Country	United Kingdom
Sector	Private
PI Contribution	University of Strathclyde is the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution	Clairet Scientific Ltd are Tier 2 members of CMAC
Impact	CMAC Future Manufacturing Research Hub works with Tier 2 Technology providers to solve specific challenges as part of the overall research programme
Start Year	2017


Description	Collaboration with the ISCF Digital Design Accelerator Platform (DDAP)
Organisation	AstraZeneca
Country	United Kingdom
Sector	Private
PI Contribution	Project name: Digital Design Accelerator Project to Connect Active Material Design to Product Performance Provided models and data for the development of new tools on the project. Provided software development capacity via ARTICULAR RAs.
Collaborator Contribution	Data were provided to validate our AI models (large pharma: AZ, GSK, Pfizer). Partners provided end users to test our tools and interfaces.
Impact	New data analysis and handling capabilities that can work with data across pharmaceutical organisations
Start Year	2019


Description	Collaboration with the ISCF Digital Design Accelerator Platform (DDAP)
Organisation	GlaxoSmithKline (GSK)
Department	Research and Development GSK
Country	United Kingdom
Sector	Private
PI Contribution	Project name: Digital Design Accelerator Project to Connect Active Material Design to Product Performance Provided models and data for the development of new tools on the project. Provided software development capacity via ARTICULAR RAs.
Collaborator Contribution	Data were provided to validate our AI models (large pharma: AZ, GSK, Pfizer). Partners provided end users to test our tools and interfaces.
Impact	New data analysis and handling capabilities that can work with data across pharmaceutical organisations
Start Year	2019


Description	Collaboration with the ISCF Digital Design Accelerator Platform (DDAP)
Organisation	Pfizer Inc
Department	Pfizer Ltd
Country	United Kingdom
Sector	Private
PI Contribution	Project name: Digital Design Accelerator Project to Connect Active Material Design to Product Performance Provided models and data for the development of new tools on the project. Provided software development capacity via ARTICULAR RAs.
Collaborator Contribution	Data were provided to validate our AI models (large pharma: AZ, GSK, Pfizer). Partners provided end users to test our tools and interfaces.
Impact	New data analysis and handling capabilities that can work with data across pharmaceutical organisations
Start Year	2019


Description	EDEM / Alatair - are Tier 2 Members of CMAC - Hub
Organisation	Altair Engineering Ltd
Country	United Kingdom
Sector	Private
PI Contribution	University of Strathclyde is the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution	EDEM / Alatair are Tier 2 members of CMAC
Impact	CMAC Future Manufacturing Research Hub works with Tier 2 Technology providers to solve specific challenges as part of the overall research programme
Start Year	2017


Description	GSK - are Tier 1 Members of CMAC - Hub
Organisation	GlaxoSmithKline (GSK)
Country	Global
Sector	Private
PI Contribution	University of Strathclyde are the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution	AstraZeneca are Tier 1 members of CMAC
Impact	CMAC Future Manufacturing Research Hub governance includes Tier 1 inputs to Industry Board and Technical Committee. Tier 1s are involved in Mentor Groups and Placements for PhD students, and other researchers.
Start Year	2017


Description	Lilly are Tier 1 Members of CMAC - Hub
Organisation	Eli Lilly & Company Ltd
Department	Neuroscience Eli Lilly
Country	United States
Sector	Private
PI Contribution	University of Strathclyde are the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution	Lilly are Tier 1 members of CMAC
Impact	CMAC Future Manufacturing Research Hub governance includes Tier 1 inputs to Industry Board and Technical Committee. Tier 1s are involved in Mentor Groups and Placements for PhD students, and other researchers.
Start Year	2017


Description	M-Star are Tier 2 Members of CMAC - Hub
Organisation	M-Star Simulations LLC
Country	United States
Sector	Private
PI Contribution	University of Strathclyde is the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution	M-Star are Tier 2 members of CMAC
Impact	CMAC Future Manufacturing Research Hub works with Tier 2 Technology providers to solve specific challenges as part of the overall research programme.
Start Year	2021


Description	Nitech
Organisation	NiTech Solutions Ltd
Country	United Kingdom
Sector	Private
PI Contribution	University of Strathclyde is the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution	Nitech are Tier 2 members of CMAC
Impact	CMAC Future Manufacturing Research Hub works with Tier 2 Technology providers to solve specific challenges as part of the overall research programme
Start Year	2017


Description	Novartis are Tier 1 Members of CMAC - Hub
Organisation	Novartis
Country	Global
Sector	Private
PI Contribution	University of Strathclyde are the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution	Novartis are Tier 1 members of CMAC
Impact	CMAC Future Manufacturing Research Hub governance includes Tier 1 inputs to Industry Board and Technical Committee. Tier 1s are involved in Mentor Groups and Placements for PhD students, and other researchers.
Start Year	2017


Description	PWC -Tier 2 Members of CMAC - Hub
Organisation	Price Waterhouse Cooper
Country	United Kingdom
Sector	Private
PI Contribution	University of Strathclyde is the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution	PWC are Tier 2 members of CMAC
Impact	CMAC Future Manufacturing Research Hub works with Tier 2 Technology providers to solve specific challenges as part of the overall research programme
Start Year	2017


Description	Perceptive Enginnering Ltd / Applied Materials are Tier 2 Members of CMAC - Hub
Organisation	Perceptive Engineering Ltd
Country	United Kingdom
Sector	Private
PI Contribution	University of Strathclyde is the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution	Perceptive Enginnering Ltd / Applied Materials are Tier 2 members of CMAC
Impact	CMAC Future Manufacturing Research Hub works with Tier 2 Technology providers to solve specific challenges as part of the overall research programme. In this case it was implementing PharmaMV on process equipment.
Start Year	2017


Description	Pfizer are Tier 1 Members of CMAC - Hub
Organisation	Pfizer Inc
Department	Pfizer Ltd
Country	United Kingdom
Sector	Private
PI Contribution	University of Strathclyde are the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution	Pfizer are Tier 1 members of CMAC
Impact	CMAC Future Manufacturing Research Hub governance includes Tier 1 inputs to Industry Board and Technical Committee. Tier 1s are involved in Mentor Groups and Placements for PhD students, and other researchers.
Start Year	2017


Description	Roche are Tier 1 Members of CMAC - Hub
Organisation	Roche Pharmaceuticals
Country	Global
Sector	Private
PI Contribution	University of Strathclyde are the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution	Roche are Tier 1 members of CMAC
Impact	CMAC Future Manufacturing Research Hub governance includes Tier 1 inputs to Industry Board and Technical Committee. Tier 1s are involved in Mentor Groups and Placements for PhD students, and other researchers.
Start Year	2017


Description	Siemens (PSE) are Tier 2 Members of CMAC - Hub
Organisation	Siemens AG
Department	Siemens plc
Country	United Kingdom
Sector	Private
PI Contribution	University of Strathclyde is the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution	Siemens (PSE) are Tier 2 members of CMAC. The work specifically is on gFormulated Products and gPROMS.
Impact	CMAC Future Manufacturing Research Hub works with Tier 2 Technology providers to solve specific challenges as part of the overall research programme
Start Year	2017


Description	Sirius Analytical are Tier 2 Members of CMAC - Hub
Organisation	Syrius Analytical Instruments Ltd
Country	United Kingdom
Sector	Private
PI Contribution	University of Strathclyde is the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution	Sirius Analytical were Tier 2 members of CMAC
Impact	CMAC Future Manufacturing Research Hub works with Tier 2 Technology providers to solve specific challenges as part of the overall research programme
Start Year	2017


Description	Takeda - are Tier 1 Members of CMAC - Hub
Organisation	Takeda Pharmaceutical Company
Department	Takeda Pharmaceuticals U.S.A., Inc. (TPUSA)
Country	United States
Sector	Private
PI Contribution	University of Strathclyde are the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution	Takeda are Tier 1 members of CMAC
Impact	CMAC Future Manufacturing Research Hub governance includes Tier 1 inputs to Industry Board and Technical Committee. Tier 1s are involved in Mentor Groups and Placements for PhD students, and other researchers.
Start Year	2017


Description	UCB - are Tier 1 Members of CMAC - Hub
Organisation	UCB SA
Country	Belgium
Sector	Private
PI Contribution	University of Strathclyde are the lead organisation of the CMAC Future Manufacturing Research Hub
Collaborator Contribution	UCB are Tier 1 members of CMAC
Impact	CMAC Future Manufacturing Research Hub governance includes Tier 1 inputs to Industry Board and Technical Committee. Tier 1s are involved in Mentor Groups and Placements for PhD students, and other researchers.
Start Year	2022


Title	CrystalGrowthTracker: A Python package to analyse crystal face advancement rates from time lapse synchrotron radiography
Description	Software developed for the extraction of crystal growth rates from 2D shadowgraphs of crystals precipitating onto a substrate, taken using X-rays of synchrotron radiation.
Type Of Technology	Software
Year Produced	2022
Open Source License?	Yes
URL	https://zenodo.org/record/7233986


Title	CrystalGrowthTracker: A Python package to analyse crystal face advancement rates from time lapse synchrotron radiography
Description	Software developed for the extraction of crystal growth rates from 2D shadowgraphs of crystals precipitating onto a substrate, taken using X-rays of synchrotron radiation.
Type Of Technology	Software
Year Produced	2022
Open Source License?	Yes
URL	https://zenodo.org/record/7233987


Description	03 April 2017 edition of Chemistry World. "The flow revolution"
Form Of Engagement Activity	A magazine, newsletter or online publication
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Professional Practitioners
Results and Impact	Article in Chemistry World Magazine that includes CMAC
Year(s) Of Engagement Activity	2017
URL	https://www.chemistryworld.com/feature/the-flow-revolution/2500496.article


Description	16 November , The Scotsman, "Fast-track medicine base in Scotland could be a game changer" .
Form Of Engagement Activity	A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Public/other audiences
Results and Impact	Article about CMAC in Scotsman newspaper / online
Year(s) Of Engagement Activity	2017
URL	https://www.scotsman.com/business/fast-track-medicine-base-in-scotland-could-be-a-game-changer-1-461...


Description	18 December 2017 - CMAC Welcomes Pfizer as Newest Partner
Form Of Engagement Activity	A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Media (as a channel to the public)
Results and Impact	Press release to announce that Pfizer joined CMAC as tier 1 Industry Partners
Year(s) Of Engagement Activity	2018
URL	http://www.strath.ac.uk/whystrathclyde/news/cmacwelcomespfizerasnewestpartner/


Description	2021 Kuopio: Prodrug technology and Continuous processing workshops & Meeting
Form Of Engagement Activity	A talk or presentation
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Postgraduate students
Results and Impact	Kuopio: Prodrug technology and Continuous processing workshops & Meeting with FinPharmaNet for graduate students (online, 27-28th Aug 2021) https://nordicpop.ku.dk/events/kuopio-meeting-together-with-finpharmanet-meeting-for-graduate-students/# 11:15 - 11:45 Challenges and opportunities for real-time release testing in continuous tablet manufacturing / Dr. Daniel Markl, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, UK 12:30 - 13:00 Developing a continuous drug substance manufacturing process / Dr. Cameron Brown, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, UK
Year(s) Of Engagement Activity	2021
URL	https://nordicpop.ku.dk/events/kuopio-meeting-together-with-finpharmanet-meeting-for-graduate-studen...


Description	24 May 2017 , Pharmaceutical Online "Developing Mobile Continuous Process Technology: A Collaborative Innovation Case Study" .
Form Of Engagement Activity	A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Public/other audiences
Results and Impact	Press release about CMAC and REMEDIES project
Year(s) Of Engagement Activity	2017
URL	https://www.pharmaceuticalonline.com/doc/developing-mobile-continuous-process-technology-a-collabora...


Description	26 January 2017 edition of Chemical Engineer Magazine "Continuous Collaboration" .
Form Of Engagement Activity	A magazine, newsletter or online publication
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Professional Practitioners
Results and Impact	Article in Chemical Engineer Magazine that outlines the CMAC activities including research, training, facilities and translation into industry.
Year(s) Of Engagement Activity	2017
URL	https://www.thechemicalengineer.com/features/continuous-collaboration/


Description	28th November , featured in the Herald, "Alastair Florence: 'The key to success is working pre-competitively with industry'
Form Of Engagement Activity	A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Public/other audiences
Results and Impact	Article about CMAC in the Herald newspaper and online
Year(s) Of Engagement Activity	2017
URL	http://www.heraldscotland.com/business_hq/15687920.Alastair_Florence___The_key_to_success_is_working...


Description	3rd ISCMP Conference
Form Of Engagement Activity	Participation in an activity, workshop or similar
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Policymakers/politicians
Results and Impact	The 3rd CMAC-MIT International Symposium on Continuous Manufacturing of Pharmaceuticals (ISCMP) brought together pharmaceutical company end users, suppliers, regulators and academics building on how research groups, globally, might collaborate more to help drive continuous manufacture and guide the way in which new technologies and approaches in the pharmaceutical industry can transform quality, cost and service for the benefit of the patient. A key objective of the 2018 meeting was to address business, regulatory and technological barriers to increase the rate of integration of continuous manufacturing into process development. Thus, emphasis placed upon regulatory with modelling and process validation as high priority areas, in addition to business cases. The London based event had excellent attendance across the board with 300 delegates and attracted many regulatory bodies including FDA, EMA and PMDA with Dr Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research delivering the keynote. A key output from this is a White Paper, which will be published in the forthcoming year (2019/2020).
Year(s) Of Engagement Activity	2018
URL	https://www.iscmp2018.org/


Description	Accelerating the delivery of new drugs to patients
Form Of Engagement Activity	A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Media (as a channel to the public)
Results and Impact	25 June Accelerating the delivery of new drugs to patients - ARTICULAR announced.
Year(s) Of Engagement Activity	2018
URL	https://www.strath.ac.uk/whystrathclyde/news/acceleratingthedeliveryofnewdrugstopatients/


Description	Advanced Characterisation using Time of Flight Secondary Ion Mass Spectrometry (ToF-SIMS) Online Workshop
Form Of Engagement Activity	Participation in an activity, workshop or similar
Part Of Official Scheme?	No
Geographic Reach	National
Primary Audience	Postgraduate students
Results and Impact	21st May 2021 - half day online event co-organised by CMAC and NPL. Hub PI Prof Alastair Florence and CoI Prof Gavin Halbert were speakers
Year(s) Of Engagement Activity	2021
URL	https://twitter.com/EPSRC_CMAC/status/1384778936291319811?cxt=HHwWhoCz4eHG3LcmAAAA


Description	Applied Materials software training workshop
Form Of Engagement Activity	Participation in an activity, workshop or similar
Part Of Official Scheme?	No
Geographic Reach	Local
Primary Audience	Postgraduate students
Results and Impact	A workshop for DM2 researchers to learn more about the functionality, capabilities and applications of the PE/AM software, PharmaMV.
Year(s) Of Engagement Activity	2023


Description	Attending 11th pan-European Science Conference on QbD & PAT (EU PAT 11) conference, 12-13 October 2023
Form Of Engagement Activity	Participation in an activity, workshop or similar
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Professional Practitioners
Results and Impact	The 11th EuPAT conference brings together scientists and engineers from across academia, industry, and regulatory bodies to discuss the latest developments in the field of pharmaceutical process and product development.
Year(s) Of Engagement Activity	2023
URL	https://eupat.eufeps.org/


Description	Attending the Pharma Data & Digital Medicine, 11 September 2023
Form Of Engagement Activity	Participation in an activity, workshop or similar
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Professional Practitioners
Results and Impact	Pharma Data Congress - Showcasing success in digital transformation with FAIR, data infrastructure, architecture and data digitalisation & automation in the lab and computational approaches
Year(s) Of Engagement Activity	2023
URL	https://www.rsc.org/events/detail/75804/pharma-data-and-digital-medicine-2023


Description	CMAC Open Day 2018
Form Of Engagement Activity	Participation in an activity, workshop or similar
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Industry/Business
Results and Impact	The CMAC Open Day 2018 showcased the research outputs of the Future CMAC Hub through a packed programme of talks, posters, interactive demonstrations, a VR/AR demo and a tour that included a live demo of a prototype Lovastatin Microfactory and digital twin devloped as part of the CMAC Future Manufacturing research Hub research programme. Additionally, there were keynotes from Prof Marianthi Ierapetritou, Rutgers University and Prof Jon-Paul Sherlock, AstraZeneca and Chair of the CMAC Advisory Board. There were 260 delegates from 76 organisations in attendance including 22 exhibitors from technology companies. All CMAC researchers presented a poster during the poster session. The talks and posters related directly to the Lovastatin Microfactory and digital twin were: Talks Arjmandi-Tash, O.; Tew, J.D.; Yusoff, S.N.M.; Pitt, K.; Smith, R.; Litster, J. Mechanistic Modelling of Spherical Agglomeration. CMAC Open Day, Glasgow 25-26th October 2018 Brown, C.J.; Application of Process Models to Microfactories. CMAC Open Day 2018, Glasgow 25-26th October 2018 Hatcher, L. E.; Control of Lovastatin Crystal Shape and Size by Additive Crystallisation Methods CMAC Open Day. University of Strathclyde, Glasgow, 25-26th October 2018 Robertson, J.; Overview of CMAC Hub Microfactories. CMAC Open Day 2018, Glasgow 25-26th October 2018 Turner, T; The Intermolecular Synthon Analysis Associated with the Morphology and Surface Properties of the API Lovastatin. CMAC Open Day 2018, Glasgow 25-26th October 2018 Posters Arjmandi-Tash, O.; Tew, J.D.; Yusoff, S.N.M.; Pitt, K.; Smith, R.; Litster, J. Mechanistic modelling of spherical agglomeration for continuous manufacturing of pharmaceuticals. CMAC Open Day. University of Strathclyde, Glasgow, 25-26th October 2018 Hatcher, L. E.; Influence of Temperature and Additive Crystallisation Methods on Lovastatin Crystal Size and Shape; CMAC Open Day: University of Strathclyde, Glasgow, 25-26th October 2018 Jolliffe, H.G., Papathanasiou, F., Prasad E., Robertson J., Brown C.J., Halbert G., Florence A.J.; Predicting multi-component tablet properties from pure component parameters. CMAC Open Day. University of Strathclyde, Glasgow, 25-26th October 2018 McGinty, J.; Developing a Workflow for Continuous Antisolvent Crystallisation. CMAC Open Day. University of Strathclyde, Glasgow, 25-26th October 2018 Pallipurath, A.; Advanced Characterisation of Lovastatin: A Theoretical and Experimental Perspective. CMAC Open Day. University of Strathclyde, Glasgow, 25-26th October 2018 Prasad, E.; Evaluation of gFormulate Modelling Tools for Tablet Compression. CMAC Open Day, University of Strathclyde, Glasgow, 25-26th October 2018 Robertson, M.; The CMAC Digital Platform. CMAC Open Day, University of Strathclyde, Glasgow, 25-26th October 2018 Tew, J.D.; Arjmandi-Tash, O.; Pitt, K.; Smith, R.; Litster, J. Wetting & Nucleation: Developing the Mechanistic Understanding of Spherical Agglomeration. CMAC Open Day. University of Strathclyde, Glasgow, 25-26th October 2018 Vassileiou, A.; Using Machine Learning to Enhance Mechanistic Solubility Predictions. CMAC Open Day, University of Strathclyde, Glasgow, 25-26th October 2018 Watson, O. L.; Galindo, A.; Jackson, G.; Adjiman, C. S. Computer-aided design of solvent blends for the cooling and anti-solvent crystallisation of lovastatin and ibuprofen. CMAC Open Day, University of Strathclyde, Glasgow, 25-26th October 2018
Year(s) Of Engagement Activity	2018


Description	CMAC PhD Mini-Symposia (Online)
Form Of Engagement Activity	Participation in an activity, workshop or similar
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Industry/Business
Results and Impact	A series of online mini-symposia were held in summer 2021 where CMAC PhD researchers presented their work to the CMAC Tier 1 partners.
Year(s) Of Engagement Activity	2021


Description	CMAC REF 2021 Submission Published
Form Of Engagement Activity	A magazine, newsletter or online publication
Part Of Official Scheme?	No
Geographic Reach	National
Primary Audience	Media (as a channel to the public)
Results and Impact	Jun 22, 2022: the REF2021 impact case study was published meaning we can now share CMAC's world leading submission - see https://results2021.ref.ac.uk/impact/fd8e9335-cb2e-44dc-b3af-85fe069ce2fe?page=2 £45 million in savings across 22 multinational and SME's for ??our research in #ContinuousManufacturing #Pharmaceuticals #Innovation
Year(s) Of Engagement Activity	2022


Description	CMAC UK Showcase Event
Form Of Engagement Activity	Participation in an activity, workshop or similar
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Supporters
Results and Impact	CMAC held a US Showcase for Tier 1s, Tier 2s and Hub academics, and members of the independent advisory board for the Hub at TIC, University of Strathclyde, Glasgow on 23rd October 2019. This aim of this event was to promote and widen engagement within the CMAC network by highlighting the broad range of activities taking place. The agenda included talks, Tier 1&2 Industry partner speed dating and an interactive Showcase of CMAC research. The CMAC research showcase covered 35 stations in 5 zones. Each station was either a live lab demo, an interactive demo of a model or digital tool or a poster. This allowed visitors to get a flavour of the braod research portfolio across CMAC, and talk with researchers about the work being showcased. Then there was a keynote and launch of white paper drafted as result of ISCMP 2018.
Year(s) Of Engagement Activity	2019


Description	CMAC US Showcase, Boston 2019
Form Of Engagement Activity	Participation in an activity, workshop or similar
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Supporters
Results and Impact	CMAC held a US Showcase for Partners - Industry Tier 1s, Industry Tier 2s and Hub academics at Takeda, Boston on 1st & 2nd May 2019. This aim of this event was to promote and widen engagement within the CMAC network by highlighting the broad range of activities taking place. AZ, Eli Lilly, Pfizer and Takeda all presented on current status in Continuous Manufacture within their respective organisations and how this fits within their business plan. Nine Tier 2 companies attended, giving a snapshot of ongoing collaborations with CMAC which was very well received. Hub research updates were presented by academics across the CMAC network including Rachel Smith, Cameron Brown, John Robertson, Brahim Benyahia, Chris Price, Blair Johnston and Daniel Markl. The event concluded with a Keynote from Alastair Florence on, 'Transforming Medicines Development and Manufacture through Microfactories and Digital Twins'. The standard of all presentations was excellent, allowing the audience to see how the range of partners and activity in this area allows us to facilitate acceleration of our research efforts.
Year(s) Of Engagement Activity	2019


Description	CMAC Virtual Open Day 2020
Form Of Engagement Activity	Participation in an activity, workshop or similar
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Industry/Business
Results and Impact	CMAC Virtual Open Day 2020 took place on the afternoons of 21-22nd Oct on the HopIn platform. The event this year was virtual due to COVID restrictions. We made the most of the opportunity to reach a wider international audience. Number of delegates: we had 365 registrations, and around 180-190 people active in the platform at any one time during both days of the event. Day 1 had talks from senior figures from the UK Medicines Manufacturing community and funders and a panel session. 11 Tier 2 exhibits: Anatune; Alconbury Weston Ltd.; Britest; CCDC; Clairet Scientific Ltd.; M-Star Simulations; Nitech Solutions Ltd.; Perceptive Engineering Ltd.; PSE; Technobis; and ThermoFisher. The rest of the event disseminated recent CMAC research. CMAC Talks: 1. Bresciani, M., Industrial Perspective, CMAC Virtual Open Day Oct 2020. 2. Brown, C., MicroFactory, CMAC Virtual Open day 2020. 3. Florence, A., CMAC Hub Update, CMAC Virtual Open Day 2020. 4. Johnston, B., Digital Platform, CMAC Virtual Open Day 2020. 5. Srai, J.S., Supply Chain, CMAC Virtual Open day 2020. 6. Schroeder, S., Know What You Don't Know: Process Design and Control of Product Attributes with Advanced X-ray Methods, CMAC Virtual Open Day, 2020. 7. Sharratt, P., Staying ahead of the game, CMAC Virtual Open Day 2020. 8. Smith, R., Digital Design Models, CMAC Virtual Open Day 2020. Breakout Flash Presentations: 1. Ahmed, B., Spherical agglomeration: workflow development, CMAC Virtual Open Day, 21-22 Oct 2020. 2. Anandan, P., Controlling batch crystallisation process using reinforcement learning, CMAC Virtual Open Day, 21-22 Oct 2020. 3. Bernet, T., Hands-on software demonstration of solubility calculations with SAFT-? Mie including mixed solvents and impurities, CMAC Virtual Open Day, 21-22 Oct 2020. 4. Brown, C., Digital design of end-to-end manufacturing process for Mefenamic Acid, CMAC Virtual Open Day, 21-22 Oct 2020. 5. Chong, M., Aligning measurements with the QbDD approach, CMAC Virtual Open Day, 21-22 Oct 2020. 6. Doerr, F., Small-scale parameter estimation on Crystalline through image analysis and translation to PBE model including error propagation for 1st crystallisation, CMAC Virtual Open Day, 21-22 Oct 2020. 7. Jolliffe, H., Medicines Manufacturing Innovation Centre (MMIC): the use of a Digital Twin, CMAC Virtual Open Day, 21-22 Oct 2020. 8. Kathyola, T., Multi-scale understanding of Lovastatin crystallisation, CMAC Virtual Open Day, 21-22 Oct 2020. 9. Li, W., Continuous crystallisation development from batch experimental data to modelling of kinetics estimation/optimisation to experimental validation for second crystallisation., CMAC Virtual Open Day, 21-22 Oct 2020. 10. Marce Villa, P., Feasibility workflow: integration of continuous synthesis and crystallisation, CMAC Virtual Open Day, 21-22 Oct 2020. 11. McGinty, J., Developing a workflow for continuous antisolvent crystallisation, CMAC Virtual Open Day, 21-22 Oct 2020. 12. Mendez, C., Development of methods to assess mixing efficiency in commercial tablet manufacture, CMAC Virtual Open Day, 21-22 Oct 2020. 13. Ojo, E., Towards the prediction of direct-compaction of multicomponent drug product formulation, CMAC Virtual Open Day, 21-22 Oct 2020. 14. Ottoboni, S., Model based design and optimisation: filtration and washing parameters estimation and strategies implementation. Linking crystallisations through isolatio, CMAC Virtual Open Day, 21-22 Oct 2020. 15. Ottoboni, S., Novel rational approach to design purification solvent selection based on isolation: workflow approach assisted by predictive and modelling tools, CMAC Virtual Open Day, 21-22 Oct 2020. 16. Pallipurath, A., Towards rational design and control of crystallisation processes, CMAC Virtual Open Day, 21-22 Oct 2020. 17. Portela, V., An immersive training environment for the assembly of an EasyMax chemical stirrer, CMAC Virtual Open Day, 21-22 Oct 2020 18. Prakash, A., ToF-SIMS in pharmaceutical manufacturing, CMAC Virtual Open Day, 21-22 Oct 2020. 19. Prasad, E., Improving consistency for a Mefenamic acid immediate release formulation, CMAC Virtual Open Day, 21-22 Oct 2020. 20. Rajoub, N., Spherical agglomeration: workflow development, CMAC Virtual Open Day, 21-22 Oct 2020. 21. Robertson, M., Exploring the CMAC data strategy: digital workflows and risk mapping, CMAC Virtual Open Day, 21-22 Oct 2020. 22. Settanni, E., MicroFactory supply chain design, CMAC Virtual Open Day, 21-22 Oct 2020. 23. Srirambhatla, V., Machine learning approaches to predict glass forming ability and morphology of pharmaceutical compounds, CMAC Virtual Open Day, 21-22 Oct 2020. 24. Vassileiou, A., Combined AI techniques for particle sizing directly from microscope images, CMAC Virtual Open Day, 21-22 Oct 2020. 25. Vassileiou, A., Solubility prediction by machine learning and a survey of solvates in the CSD, CMAC Virtual Open Day, 21-22 Oct 2020. 26. Warzecha, M., Understanding the adsorption of impurities on crystal faces using molecular modelling and atomic force microscopy, CMAC Virtual Open Day, 21-22 Oct 2020. 27. Watson, O., Demonstrating the selection of optimal solvent mixtures for the crystallisation of APIs in gPROMS/gSAFT, CMAC Virtual Open Day, 21-22 Oct 2020. 30. Willneff, E., Linking molecule to product with environmental X-ray Photoelectron Spectroscopy, CMAC Virtual Open Day, 21-22 Oct 2020. Posters: 1. Abdallah, N., In situ monitoring of the cooling crystallisation of mefenamic acid using Raman, Terahertz-Raman and ATR-UV spectroscopies, CMAC Virtual Open Day, 21-22 Oct 2020. 2. Ahmed, B., Spherical agglomeration: workflow development, CMAC Virtual Open Day, 21-22 Oct 2020. 3. Alsuleman, M., Material based decision for formulating a 3D printing filament, CMAC Virtual Open Day, 21-22 Oct 2020. 4. Anandan, P., Controlling batch crystallisation process using reinforcement learning, CMAC Virtual Open Day, 21-22 Oct 2020. 5. Bernet, T., SAFT-? Mie modelling of groups and complex molecules; parameter estimation framework and performance, CMAC Virtual Open Day, 21-22 Oct 2020. 6. Blazejczak, M., MMIC: Developing next-generation pharmaceutical manufacturing, CMAC Virtual Open Day, 21-22 Oct 2020. 7. Bordos, E., Effect of material and process parameters on the microstructure of amorphous solid dispersions, CMAC Virtual Open Day, 21-22 Oct 2020. 8. Cashmore, A., A rapid and small-scale assessment of secondary nucleation and growth kinetics of ?-glycine, CMAC Virtual Open Day, 21-22 Oct 2020. 9. Chong, M., Temperature correction of UV spectra for improved concentration monitoring during cooling crystallisation, CMAC Virtual Open Day, 21-22 Oct 2020. 10. Creswick, J., Analysis of novel spherical agglomerate tablets: fragmentation quantification and impact on tablet performance, CMAC Virtual Open Day, 21-22 Oct 2020. 11. Das, G., Time-resolved microfocus synchrotron X-ray Phase Contrast Imaging (XPCI) - a versatile tool for predictive design and control of crystallisation processes, CMAC Virtual Open Day, 21-22 Oct 2020. 12. Devlin, M., Structure and transformations in amorphous Paracetamol, CMAC Virtual Open Day, 21-22 Oct 2020. 13. Doerr, F., Model-based design and optimisation of crystallisation processes: image analysis methodologies for small scale parameter estimation, CMAC Virtual Open Day, 21-22 Oct 2020. 14. Eales, W., Measuring and modelling agglomeration and breakage during agitated vacuum thermal drying, CMAC Virtual Open Day, 21-22 Oct 2020. 15. Flannigan, J., An investigation of secondary nucleation at the microscale using optical tweezing, CMAC Virtual Open Day, 21-22 Oct 2020. 16. Hou, P., Design of a micro-feeder for solid pharmaceuticals, CMAC Virtual Open Day, 21-22 Oct 2020. 17. Johnston, J., Model-driven controller design for continuous crystallisation of ?-Lactose Monohydrate, CMAC Virtual Open Day, 21-22 Oct 2020. 18. Jolliffe, H., Medicines Manufacturing Innovation Centre (MMIC): the use of a Digital Twin, CMAC Virtual Open Day, 21-22 Oct 2020. 19. Jonuzaj, S., Solvent mixture design and optimisation for the integrated crystallisation and isolation of Mefenamic Acid, CMAC Virtual Open Day, 21-22 Oct 2020. 20. Kathyola, T., X-ray scattering and X-ray Photoelectron Spectroscopy analysis of Mefenamic Acid thermal-induced polymorphism, CMAC Virtual Open Day, 21-22 Oct 2020. 21. Kitching, V., The influence of vessel and agitator geometry and speed on flow characteristics in spherical agglomerators, CMAC Virtual Open Day, 21-22 Oct 2020. 22. Li, W., Model-based design and optimization of multistage mixed suspension mixed product removal crystallization of Mefenamic Acid, CMAC Virtual Open Day, 21-22 Oct 2020. 23. Mack, C., Thermodynamics in Antisolvent Phase Diagrams: Methodology Development and Molecular Interactions, CMAC Virtual Open Day, 21-22 Oct 2020. 24. Mahon, J., Investigating structural changes of amorphous solid dispersions during dissolution, CMAC Virtual Open Day, 21-22 Oct 2020. 25. Marce Villa, P., Feasibility workflow: integration of continuous synthesis and crystallisation, CMAC Virtual Open Day, 21-22 Oct 2020. 26. McGinty, J., Developing a workflow for continuous antisolvent crystallisation, CMAC Virtual Open Day, 21-22 Oct 2020. 27. McKechnie, D., Tuning dispersion interactions to control heterogeneous nucleation, CMAC Virtual Open Day, 21-22 Oct 2020. 28. Mendez, C., Development of methods to assess mixing efficiency in commercial tablet manufacture, CMAC Virtual Open Day, 21-22 Oct 2020. 29. Miller, R., Modelling diffusive mixing in continuous antisolvent crystallisation, CMAC Virtual Open Day, 21-22 Oct 2020. 30. Mnemo, M., Digital design strategies for industrial crystallisation development, CMAC Virtual Open Day, 21-22 Oct 2020. 31. Murphy, K., Analysis of terahertz scattering of granular materials, CMAC Virtual Open Day, 21-22 Oct 2020. 32. Nakapraves, S., Machine learning approaches for predictive design of the crystal shape of Mefenamic Acid, CMAC Virtual Open Day, 21-22 Oct 2020. 33. Ojo, E., Multistage, multi-zones antisolvent-cooling crystallisation of a proprietary API: Experimental comparison of effect of geometry and hydrodynamics in four batch crystallisers, CMAC Virtual Open Day, 21-22 Oct 2020. 34. Ottoboni, S., Understanding API static drying with hot gas flow: design and test of a drying rig prototype and drying modelling development, CMAC Virtual Open Day, 21-22 Oct 2020. 35. Pallipurath, A., Towards rational design and control of crystallisation processes, CMAC Virtual Open Day, 21-22 Oct 2020. 36. Pallipurath, A. R., Insights into thermodynamic solution properties from X-ray Pair Distribution Function analysis, CMAC Virtual Open Day, 21-22 Oct 2020. 37. Payne, P., Benchmarking the CMAC additive and multicomponent screening workflows, CMAC Virtual Open Day, 21-22 Oct 2020. 38. Pereira-Diaz, L., Coupling primary and secondary manufacturing via digital design of crystalline materials, CMAC Virtual Open Day, 21-22 Oct 2020. 39. Portela, V., An immersive training environment for the assembly of an EasyMax chemical stirrer, CMAC Virtual Open Day, 21-22 Oct 2020. 40. Powell, D., Protein Nucleation in microfluidic devices, CMAC Virtual Open Day, 21-22 Oct 2020. 41. Prakash, A., ToF-SIMS in pharmaceutical manufacturing, CMAC Virtual Open Day, 21-22 Oct 2020. 2020. 42. Prasad, E., Improving consistency for a Mefenamic acid immediate release formulation, CMAC Virtual Open Day, 21-22 Oct 2020. 43. Prostredny, M., MMIC Grand Challenge 1: Process equipment and facilities, CMAC Virtual Open Day, 21-22 Oct 2020. 44. Robertson, M., Exploring the CMAC data strategy: digital workflows and risk mapping, CMAC Virtual Open Day, 21-22 Oct 2020. 45. Sanxaridou, G., Mechanical properties of agglomerates produced by two different drying methods, CMAC Virtual Open Day, 21-22 Oct 2020. 46. Settanni, E., MicroFactory supply chain design, CMAC Virtual Open Day, 21-22 Oct 2020. 47. Shahid, M., Employing constant rate filtration to improve active pharmaceutical ingredients (APIs) washing efficiency, CMAC Virtual Open Day, 21-22 Oct 2020. 48. Siddique, M., Quantification of granule formation during drying as a function of solubility in residual solvents, CMAC Virtual Open Day, 21-22 Oct 2020. 49. Smith, K., CMAC National Facility short case studies, CMAC Virtual Open Day, 21-22 Oct 2020. 50. Soundaranathan, M., Quantification of swelling characteristics of pharmaceutical particles, CMAC Virtual Open Day, 21-22 Oct 2020. 51. Srirambhatla, V., Machine learning approach for the prediction of glass-forming ability of pharmaceutical compounds, CMAC Virtual Open Day, 21-22 Oct 2020. 52. Straughair, L., Analysis of organic crystals containing solvents in the CSD, CMAC Virtual Open Day, 21-22 Oct 2020. 53. Tew, J., A mechanistic study of wetting & nucleation in spherical agglomeration, CMAC Virtual Open Day, 21-22 Oct 2020. 54. Totten, J., Impact of silk stock on nanoparticle assembly and characteristics, CMAC Virtual Open Day, 21-22 Oct 2020. 55. Vassileiou, A., Combined AI techniques for particle sizing directly from microscope images, CMAC Virtual Open Day, 21-22 Oct 2020. 56. Vassileiou, A., Solubility prediction by machine learning and a survey of solvates in the CSD, CMAC Virtual Open Day, 21-22 Oct 2020. 57. Vivattanaseth, P., In situ monitoring of hot melt extrusion with Terahertz (THz) - Raman spectroscopy, CMAC Virtual Open Day, 21-22 Oct 2020. 58. Walsh, E., Manufacturing tablets with desired specific surface area, CMAC Virtual Open Day, 21-22 Oct 2020. 59. Ward, M., Recovery of high-pressure solid forms to ambient pressures, CMAC Virtual Open Day, 21-22 Oct 2020. 60. Warzecha, M., Understanding the adsorption of impurities on crystal faces using molecular modelling and atomic force microscopy, CMAC Virtual Open Day, 21-22 Oct 2020. 61. Watson, O., Computer-aided solvent selection for the control of crystal morphology of pharmaceutical compounds, CMAC Virtual Open Day, 21-22 Oct 2020. 62. Wilkinson, M., Applying machine learning to the prediction of crystal morphology, CMAC Virtual Open Day, 21-22 Oct 2020.
Year(s) Of Engagement Activity	2020


Description	CMAC X-ray youtube channel
Form Of Engagement Activity	A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme?	No
Geographic Reach	National
Primary Audience	Public/other audiences
Results and Impact	CMAC X-ray youtube channel 3 videos added: Pound coin CT, Paracetamol capsule analysis, Tablet coating analysis https://www.youtube.com/channel/UCNWMxJQVvxmn_VynR53fIYA
Year(s) Of Engagement Activity	2019
URL	https://www.youtube.com/channel/UCNWMxJQVvxmn_VynR53fIYA


Description	CMAC contribution to UKRI #EPSRCBuildingResilience: Sustainable, cost-effective medicine manufacturing
Form Of Engagement Activity	A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Public/other audiences
Results and Impact	Video case study was published by UKRI, CMAC Director and Hub PI, Prof Alastair Florence was interviewed, and filming done at the CMAC National Facility in TIC, University of Strathclyde. It describes the benefits of digital twins in medicines manufacturing, and shows the equipment being used in the labs by the Hub team and the digital twin graphics.
Year(s) Of Engagement Activity	2021
URL	https://www.youtube.com/watch?v=ix6rP6_QnZY


Description	CMAC was an exhibitor at the Scottish Science Advisory Council (SSAC) Reception Jan 2019
Form Of Engagement Activity	Participation in an activity, workshop or similar
Part Of Official Scheme?	No
Geographic Reach	Regional
Primary Audience	Policymakers/politicians
Results and Impact	CMAC was an exhibitor at the Scottish Science Advisory Council (SSAC) reception on Wednesday 23rd January 2019 at Dynamic Earth in Edinburgh for the launch of Science landscape report. Both the full report and summary can be found on the SSAC website at:- http://www.scottishscience.org.uk/publications Industry Director Craig Johnston met with the Scottish Minister for Higher Education & Science, Richard Lochhead.
Year(s) Of Engagement Activity	2019


Description	Cambridge Crystallographic Data Centre (CCDC) has joined CMAC as a Tier 2 Member
Form Of Engagement Activity	A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Public/other audiences
Results and Impact	23 October Cambridge Crystallographic Data Centre (CCDC) has joined CMAC as a Tier 2 Member.
Year(s) Of Engagement Activity	2018
URL	https://www.ccdc.cam.ac.uk/News/List/2018-10-23-ccdc-joins-future-manufacturing-initiative-to-help/


Description	Chemical Engineer Article May 2018 "Continuous crystallisation workflow enables high precision manufacturing of pharmaceuticals"
Form Of Engagement Activity	A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Professional Practitioners
Results and Impact	09 May Chemical Engineer Article May 2018 "Continuous crystallisation workflow enables high precision manufacturing of pharmaceuticals" link below. Features C J Brown et al, Mol. Syst. Des. Eng., 2018, DOI: 10.1039/c7me00096k
Year(s) Of Engagement Activity	2018
URL	https://www.thechemicalengineer.com/news/continuous-crystallisation-workflow-enables-high-precision-...


Description	Chemistry World "The Case for Lab Management Systems"
Form Of Engagement Activity	Engagement focused website, blog or social media channel
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Professional Practitioners
Results and Impact	03 July edition of Chemistry World "The Case for Lab Management Systems"
Year(s) Of Engagement Activity	2018
URL	https://www.chemistryworld.com/opinion/the-case-for-lab-management-systems/3009220.article


Description	Chemistry World Article March 2018 "Solving the Crystal Maze" by Laura Fisher
Form Of Engagement Activity	A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Professional Practitioners
Results and Impact	26 March Chemistry World Article March 2018 "Solving the Crystal Maze" by Laura Fisher (26th March 2018) link below (subscribers only). Highlights the CMAC publication C J Brown et al, Mol. Syst. Des. Eng., 2018, DOI: 10.1039/c7me00096k
Year(s) Of Engagement Activity	2018
URL	https://www.chemistryworld.com/news/solving-the-crystal-maze/3008812.article


Description	Continuous manufacturing: making it real: 24th April 2019, Manufacturing Chemist
Form Of Engagement Activity	A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme?	No
Geographic Reach	National
Primary Audience	Industry/Business
Results and Impact	"Continuous manufacturing: making it real" 24th April 2019, Dr Kevin Robertson, Manufacturing Chemist https://www.manufacturingchemist.com/news/article_page/Continuous_pharma_manufacturing_making_it_real/154030 Prof. Alastair Florence, Director of the EPSRC Future Manufacturing Research Hub, Continuous Manufacturing and Advanced Crystallisation (CMAC), noted the use of continuous processes to improve both scale-down as well as scale-up, promoting miniaturisation to accelerate product development with less (valuable) API.
Year(s) Of Engagement Activity	2019
URL	https://www.manufacturingchemist.com/news/article_page/Continuous_pharma_manufacturing_making_it_rea...


Description	Doors Open Glasgow 2022
Form Of Engagement Activity	Participation in an open day or visit at my research institution
Part Of Official Scheme?	No
Geographic Reach	Local
Primary Audience	Public/other audiences
Results and Impact	CMAC are participated in the #Glasgow Doors Open Days Festival (https://glasgowdoorsopendays.org.uk) Saturday 17th September 2022 (10am-4pm) at the Technology & Innovation Centre (TIC), University of Strathclyde.
Year(s) Of Engagement Activity	2022
URL	https://glasgowdoorsopendays.org.uk/building-no-booking/technology-innovation-centre-tic-university-...


Description	EPSRC 's Executive Chair, Lynn Gladden visit & blog mention
Form Of Engagement Activity	Participation in an open day or visit at my research institution
Part Of Official Scheme?	No
Geographic Reach	National
Primary Audience	Policymakers/politicians
Results and Impact	In a new blog post, the EPSRC 's Executive Chair, Lynn Gladden, reflects on her university visits, including a visit to CMAC at University of Strathclyde. It was a pleasure to host Lynn as part of this tour, showcasing our facilities and discussing how CMAC can work with UKRI to 'transform tomorrow together'.
Year(s) Of Engagement Activity	2022
URL	https://bit.ly/3Du7kgM


Description	Future of Work in Medicines Manufacturing Round Table (interAct)
Form Of Engagement Activity	A formal working group, expert panel or dialogue
Part Of Official Scheme?	No
Geographic Reach	Regional
Primary Audience	Industry/Business
Results and Impact	Round table discussion in collaboration with InterAct to gather views, opinions and insights from our networks to help shape future skills development activities
Year(s) Of Engagement Activity	2023
URL	https://cmac.ac.uk/news-database/dm2-future-of-work-webinar


Description	Harriet Wallace, Director for International Research and Innovation, visits CMAC in TIC
Form Of Engagement Activity	Participation in an open day or visit at my research institution
Part Of Official Scheme?	No
Geographic Reach	National
Primary Audience	Policymakers/politicians
Results and Impact	Harriet Wallace, Director for International Research and Innovation, @beisgovuk visited University of Strathclyde and visited CMAC for a tour of our facilities and to discuss our research in pharmaceutical manufacturing.
Year(s) Of Engagement Activity	2021
URL	https://twitter.com/EPSRC_CMAC/status/1435218322866454529?cxt=HHwWgoCy2bzd9eonAAAA


Description	Hosted visitors from Bristol Myers Squibb & Malvern Panalytical
Form Of Engagement Activity	Participation in an open day or visit at my research institution
Part Of Official Scheme?	No
Geographic Reach	Local
Primary Audience	Postgraduate students
Results and Impact	CMAC were delighted to host visitors from Bristol Myers Squibb & Malvern Panalytical @newsfrom_MP 17th Aug 2022. Mike Tobyn (Senior Scientific Director at Bristol-Myers Squibb) gave an engaging seminar to the CMAC community titled Small Particles and Big Data.
Year(s) Of Engagement Activity	2022


Description	Hub Showcase - Sept 2024
Form Of Engagement Activity	Participation in an activity, workshop or similar
Part Of Official Scheme?	No
Geographic Reach	National
Primary Audience	Industry/Business
Results and Impact	In September 2024 CMAC hosted a Hub Showcase event, in TIC at University of Strathclyde, to disseminate the research outputs from the CMAC Future Manufacturing Research Hub and aligned activities. This was a half day event for 100 people and included a delegation from MMIP who had a VIP tour of the CMAC National Facility and saw a poster session and talks about the work that's been done.
Year(s) Of Engagement Activity	2024


Description	Huxley Bertram Press Release Nov 2020
Form Of Engagement Activity	A magazine, newsletter or online publication
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Other audiences
Results and Impact	The announcement of Huxley Bertram as Tier 2 Partner in CMAC. CMAC are pleased to announce that following the recent establishment of our new Compaction Simulation Pilot Test Facility that we can now offer Compaction Simulation Research Services through our National Facility Team. This is supported by a new partnership between Huxley Bertram and the CMAC Future Manufacturing Research Hub at the University of Strathclyde (Glasgow, UK). An HB50 Huxley Bertram Compaction Simulator specified with instrumented dies and innovative process analytics for in situ measurements using terahertz spectroscopy has recently been installed in CMAC's facilities. Compaction simulation research at CMAC is being led by academics and scientists expert in compaction simulation with cutting edge application and engineering support provided by Huxley Bertram's Cambridge-based staff. CMAC National Research Facility was established through investment from UK-RPIF, Wolfson Foundation, SFC, University of Strathclyde and our industry partners and is the only international academic facility to receive a coveted ISPE 'Facility of the Year Award'. The first in world integrated compaction simulator-terahertz system was made possible by support from EPSRC which is housed alongside suites of state-of-the-art continuous processing equipment, extensive process analytics, advanced automation & control and advanced characterisation techniques for pharmaceutical systems. The facility has a dedicated support team which offers consultancy, research services and collaboration support for both academic & industrial research & development. Compaction Simulation Services Several levels of compaction simulation research and development work are available on a contract basis: Material characterisation and advanced compaction studies of active pharmaceutical ingredients (APIs), excipients and blends. Routine powder characterisation, constitutive analyses (axial stress/strain). Compactibility/compressibility/tabletability studies. Radial analyses (instrumented dies). Advanced compaction studies: radial analyses, frictionless ejection. Die compaction (rotary press) roll compaction and capsule tamping. High-fidelity rotary presses simulation, including hybrid MODUL simulations. Material-sparing formulation and process development. Material-sparing replication of direct compression & dry granulation processes (DC/DG). Formulation assistance and optimisation including lubrication studies. Formulation design, development and scale-up. Process understanding development: Compaction understanding and materials science by pairing compaction simulation with exceptional advanced characterisation techniques: X-ray computed nanotomography, time-of-flight secondary ion mass spectrometry, etc. Compaction thermodynamics, in-die temperature evolution. Microstructure analysis using terahertz spectroscopy and X-ray computed nanotomography. Troubleshooting of clinical and commercial die compaction processes Contact us for more information CMAC Future Manufacturing Research Hub: Claire MacDonald, claire.macdonald.101@strath.ac.uk For other simulation services inquiries contact Huxley Bertram: Martin Bennett, martinwbennett@huxleybertram.com
Year(s) Of Engagement Activity	2020
URL	https://www.cmac.ac.uk/showNews.php


Description	KTN Medicines Manufacturing round table discussion (25th May 2023)
Form Of Engagement Activity	A formal working group, expert panel or dialogue
Part Of Official Scheme?	No
Geographic Reach	Local
Primary Audience	Third sector organisations
Results and Impact	Colleagues from across the DM2 and wider CMAC leadership team sat with KTN Medicines Manufacturing Manager to disucss the soon to be launched Transforming Medicines Manufacturing Community of Practice, our involvement and further opportunities to collaborate for the benefit of the project.
Year(s) Of Engagement Activity	2023


Description	Looking back to look forward
Form Of Engagement Activity	Engagement focused website, blog or social media channel
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Public/other audiences
Results and Impact	22 June Looking back to look forward - ReMEDiES article.
Year(s) Of Engagement Activity	2018
URL	https://remediesproject.com/2018/04/16/looking-back-to-look-forward-craig-johnston/


Description	MMIP working group - skills
Form Of Engagement Activity	A formal working group, expert panel or dialogue
Part Of Official Scheme?	No
Geographic Reach	National
Primary Audience	Policymakers/politicians
Results and Impact	Medicines Manufacturing Industry Partnership skills working group conducted questionnaire to assess the needs of future skillforce. This has fed directly into the Office of Life Sciences SKill Strategy 2030. Report has been launched and disseminated across governement, industry profeesionals and leading academics as well as funding bodies.
Year(s) Of Engagement Activity	2018,2019,2020
URL	https://www.scienceindustrypartnership.com/skills-issues/sip-2030-skills-strategy/


Description	Microfactory and Digital Twin Video
Form Of Engagement Activity	A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Public/other audiences
Results and Impact	24 October EPSRC CMAC Future Manufacturing Research Hub - Microfactory and Digital Twin video.
Year(s) Of Engagement Activity	2018
URL	https://www.youtube.com/watch?v=MttQ-nAs3VM


Description	New CMAC Industry Board Chair - Dr Ivan Marziano
Form Of Engagement Activity	A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Media (as a channel to the public)
Results and Impact	CMAC announced the new chair of the CMAC Industry Board by press release on the CMAC website and Twitter.
Year(s) Of Engagement Activity	2022
URL	https://cmac.ac.uk/news-database/a-new-chapter-for-cmacs-industry-board


Description	Organising the 11th pan-European Science Conference on QbD & PAT (EU PAT 11) conference workshop, 11 October 2023
Form Of Engagement Activity	Participation in an activity, workshop or similar
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Industry/Business
Results and Impact	The DM2 delivered a workshop on robotics and immersive technologies to a group of delegates from the pharma industry.
Year(s) Of Engagement Activity	2023


Description	Organising the Cambridge International Manufacturing Symposium, 21-22 September 2023
Form Of Engagement Activity	Participation in an activity, workshop or similar
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Industry/Business
Results and Impact	The annual Cambridge International Manufacturing Symposium is the chance to hear from world-leading business figures and thinkers on the challenges facing modern manufacturing.
Year(s) Of Engagement Activity	2023
URL	https://www.ifm.eng.cam.ac.uk/news/cambridge-international-manufacturing-symposium-2023/


Description	Organising the ISIC conference (5-8 September 2023)
Form Of Engagement Activity	Participation in an activity, workshop or similar
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Industry/Business
Results and Impact	Research related conference to engage stakeholders and build network
Year(s) Of Engagement Activity	2023
URL	https://www.isic2023.com/


Description	Panel at Pharma Integrates 2018
Form Of Engagement Activity	A talk or presentation
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Industry/Business
Results and Impact	Panel: Digitally Enabling Technologies for Continuous Manufacture and Regulatory Needs: Pharma Integrates 2018 (Day 2) Facilitated by: Craig Johnston Industry Director, CMAC. Video of panel https://www.lifescienceintegrates.com/videos-for-pharma-2018/
Year(s) Of Engagement Activity	2018
URL	https://www.lifescienceintegrates.com/videos-for-pharma-2018/


Description	Parliamentary Under Secretary of State visits CMAC Facilities in TIC
Form Of Engagement Activity	Participation in an open day or visit at my research institution
Part Of Official Scheme?	No
Geographic Reach	Local
Primary Audience	Policymakers/politicians
Results and Impact	Paul Scully MP, Parliamentary Under Secretary of State (Minister for Small Business, Consumers and Labour Markets) visited the CMAC National Facility in in the Technology and Innovation Centre at University of Strathlcyde during w/c 15th Feb 2022.
Year(s) Of Engagement Activity	2022
URL	https://twitter.com/EPSRC_CMAC/status/1494276562245533697?cxt=HHwWgoCyjbmn3rwpAAAA


Description	Participation at CMAC Open Days, 14-16 November 2023 (Organiser)
Form Of Engagement Activity	Participation in an open day or visit at my research institution
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Industry/Business
Results and Impact	Research related conference to engage stakeholders and build network across CMAC research portfolio. Future CMAC Hub and aligned projects posters, showcases, lab tours and talks; DM2 demonstration of research progress to date and it's researchers present talks and posters. Some talks on the YouTube Channel: https://www.youtube.com/channel/UCbic3O4IH1TLMhExyY9Utmg.
Year(s) Of Engagement Activity	2023
URL	https://cmac.ac.uk/events-database/open-days-2023


Description	Participation at PharmaTech Integrates Conference, 21 September 2023
Form Of Engagement Activity	A formal working group, expert panel or dialogue
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Industry/Business
Results and Impact	Research related conference to engage stakeholders and build network
Year(s) Of Engagement Activity	2023
URL	https://www.lifescienceintegrates.com/event/pharmatech-integrates-2023/


Description	Participation at Pharmageddon, 18-19 Ocotber 2023
Form Of Engagement Activity	Participation in an activity, workshop or similar
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Industry/Business
Results and Impact	2-day innovation experience, designed to dismantle our assumptions about the status quo and recreate a better industry for patients, HCPs, and ourselves. You will collaborate with your peers and customers to take pharma apart, and build it back better.
Year(s) Of Engagement Activity	2023
URL	https://www.eucope.org/events/pharmageddon-event/


Description	Participation at the Innovate UK Transforming Medicines Manufacturing Community of Practice - Launch Event, 4 Ocotber 2023
Form Of Engagement Activity	A formal working group, expert panel or dialogue
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Policymakers/politicians
Results and Impact	Innovate UK Transforming Medicines Manufacturing Community of Practice - Launch Event
Year(s) Of Engagement Activity	2023
URL	https://iuk.ktn-uk.org/events/transforming-medicines-manufacturing-community-of-practice-launch-even...


Description	Participation at the International Consortium for Advance Medicine Manufacturing (ICAMM), 27-28 April 2023
Form Of Engagement Activity	A talk or presentation
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Professional Practitioners
Results and Impact	The International Symposium of Continuous Manufacturing of Pharmaceutical (ISCMP) was established in 2012 and has organized three successful meetings bringing together leading scientist and technical experts from industry, academia, and global regulatory authorities. These symposia helped lay the foundation for future industry adoption and regulatory policies.
Year(s) Of Engagement Activity	2023
URL	https://cmac.ac.uk/events-database/icamm-2023


Description	Participation at the Pharma Automation & Robotics Conference 2023 (20-21 April 2023)
Form Of Engagement Activity	Participation in an activity, workshop or similar
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Professional Practitioners
Results and Impact	A Premier Meeting for Automation & Robotics R&D. DM2 Network & Skills rep attended on behalf of the project.
Year(s) Of Engagement Activity	2023
URL	https://www.pharmaceutical-tech.com/events/pharma-automation-robotics-2023


Description	Pharma Sustainability Integrates 2022
Form Of Engagement Activity	Participation in an activity, workshop or similar
Part Of Official Scheme?	No
Geographic Reach	National
Primary Audience	Industry/Business
Results and Impact	CMAC CoI Prof Chris Price presented at this event which was co-organised by MMIC partners. His talk was Manufacturing showcase: A presentation on achieving sustainable pharmaceutical manufacturing
Year(s) Of Engagement Activity	2022
URL	https://www.lifescienceintegrates.com/pharma-sustainability-integrates-agenda-2022/


Description	PharmaTech Integrates 2021 - CMAC Contribution
Form Of Engagement Activity	Participation in an activity, workshop or similar
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Industry/Business
Results and Impact	PharmaTech Integrates - https://www.lifescienceintegrates.com/pharmatech-integrates-2021/ - CMAC were an exhibitor. MASSIMO BRESCIANI, Industry Director, EPSRC Future Manufacturing Research Hub, CMAC was on Organising Committee. Technology Showcase CMAC: Digital Twins and MicroFactories. Directors, Prof Alastair Florence and Massimo Bresciani, presented on how CMAC are working on flexible integrated manufacturing technologies to accelerate product and process development, providing greater agility, sustainability and flexibility for future medicines development and manufacture. Session: Making solid progress in Continuous Direct Compression - ALASTAIR FLORENCE \| Director, Continuous Manufacturing and Advanced Crystallisation (CMAC) Research Hub \| University of Strathclyde was a panelist
Year(s) Of Engagement Activity	2021
URL	https://www.lifescienceintegrates.com/pharmatech-integrates-2021/


Description	Press Release - Laminar and UK/IRE Distributor Analytik Join CMAC - Dec 2020
Form Of Engagement Activity	A magazine, newsletter or online publication
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Other audiences
Results and Impact	Continuous flow chemical reactor manufacturer Laminar Co Ltd (Jungwon-gu, Republic of Korea), represented in the UK and Ireland by Analytik Ltd (Cambridge, UK), have joined the CMAC Future Manufacturing Research Hub as tier 2 members from October 2020. Laminar manufactures the world's first commercially available chemical reactors which utilise Taylor Fluid Flow to synthesize high-purity, uniform substances. The patented design chemical reactors use a jacketed cylindrical vessel with a central, rotating agitation bar to produce Taylor Flow mixing along the length of the vessel resulting in 3-times faster mass flow transfer compared to tank type reactors. The partnership will see the first Taylor Flow Reactor installed in the UK at CMAC's Technology Innovation Centre (TIC) site in Glasgow, which will initially be studied to greater understand the mechanisms and potential of the technology, explore new syntheses and be benchmarked against existing processes. The CMAC Future Manufacturing Research Hub brings together a research team at Strathclyde, as well as other leading academic groups and an array of industry partners to address the urgent need to translate new molecules into high-value products through rapid predictive development pathways and integrated continuous manufacturing systems. Analytik announced a partnership with Laminar to distribute their Taylor Flow Reactors in the UK and Ireland in 2019. Specialists in providing and supporting pioneering technology, it will oversee the installation of a Tera3100-HC Laminar Continuous Taylor Reactor (LCTR®) at CMAC in early 2021, as well as provide ongoing technical and service support over 3 years. Speaking about the membership, Ian Laidlaw, Managing Director at Analytik said "We are delighted to be joining the CMAC Future Manufacturing Research Hub and excited to be facilitating the first LCTR® chemical reactor installation in the UK. This fantastic technology sets a new standard for high yield synthesis of high-purity, uniform substances and offers faster, more efficient continuous processing". Professor Alastair Florence, Director of CMAC added "It is a pleasure to welcome Laminar and Analytik to CMAC's community. This partnership brings exciting new opportunities for our research team to work with this unique Taylor Flow Reactor platform to explore the potential for this advanced technology across reaction, work-up, purification and particle engineering for pharmaceutical systems. This technology will extend our Digital Twin and MicroFactory platforms for continuous manufacturing and create real benefits and impacts to our stakeholders though enabling faster process and product development and reducing the cost and environmental impact of medicines manufacture." You can find out more about Laminar Continuous Taylor Reactors (LCTR) by visiting the Analytik website: https://analytik.co.uk/product/continuous-flow-reactor/.
Year(s) Of Engagement Activity	2020
URL	https://www.cmac.ac.uk/showNews.php


Description	Queen's Anniversary Prize
Form Of Engagement Activity	A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Media (as a channel to the public)
Results and Impact	CMAC were honoured to be part of the University of Strathclyde's team that received the Queen's Anniversary Prize for Higher and Further Education at St James's Palace on 23rd Feb 2022 for our excellence in Advanced Manufacturing. The university and CMAC have posted this on their websites.
Year(s) Of Engagement Activity	2022
URL	https://cmac.squarespace.com/news-database/qap


Description	Robotics Fair at Strathclyde
Form Of Engagement Activity	Participation in an open day or visit at my research institution
Part Of Official Scheme?	No
Geographic Reach	National
Primary Audience	Postgraduate students
Results and Impact	Jan 25 2023: CMAC researchers Chantal Mustoe and Faisal Abbas took part in a Robotics Industry Fair at the University of Strathclyde. This was a great opportunity to showcase their work with robotics as part of our DataFactories and Digital Medicines Manufacturing programmes.
Year(s) Of Engagement Activity	2023


Description	Roundtable discussion: Augmented Reality Skills Development for Medicines Manufacturing R&D (10 May 2023)
Form Of Engagement Activity	A formal working group, expert panel or dialogue
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Industry/Business
Results and Impact	Round table with key project partners to gather insights on industry needs in this area to inform the DM2 skills development workpakage activities related to AR
Year(s) Of Engagement Activity	2023


Description	Science and Technology Committee visit to CMAC Facilities in TIC
Form Of Engagement Activity	Participation in an open day or visit at my research institution
Part Of Official Scheme?	No
Geographic Reach	National
Primary Audience	Policymakers/politicians
Results and Impact	Visitors from the Science and Technology Committee visited the CMAC National Facility as part of a visit to University of Strathclyde on 11th Feb 2022.
Year(s) Of Engagement Activity	2022
URL	https://twitter.com/CommonsSTC/status/1492181799522418692?cxt=HHwWiICyzZrcpbUpAAAA


Description	Scotland House Office Opens
Form Of Engagement Activity	A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Media (as a channel to the public)
Results and Impact	CMAC are take up residence at Scotland House, London, UK on 29/04/2022. We're delighted to introduce the new CMAC Central London Office. Press release on website.
Year(s) Of Engagement Activity	2022
URL	https://cmac.ac.uk/news-database/cmac-london-office


Description	Scottish Secretary of State visit
Form Of Engagement Activity	Participation in an open day or visit at my research institution
Part Of Official Scheme?	No
Geographic Reach	Regional
Primary Audience	Policymakers/politicians
Results and Impact	CMAC were happy to show Scottish Secretary of State, Lord Offord of Garvel, around our world-leading facilities at the end of July 2022 as part of his broader visit to University of Strathclyde.
Year(s) Of Engagement Activity	2022


Description	Showcased at Scotland Manufacturing and Supply Chain Conference, 25 October 2023
Form Of Engagement Activity	Participation in an activity, workshop or similar
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Public/other audiences
Results and Impact	Showcased the DM2 developed technologies and engaged with stakeholders
Year(s) Of Engagement Activity	2023
URL	https://www.sdpscotland.co.uk/events/scotland-manufacturing-supply-chain-conference-exhibition-1505/


Description	Siemens released a video of Alwyn Jones, Siemens UK & Ireland Head of Pharmaceutical & Life Sciences, in conversation with CMAC's Industry Director Craig Johnston
Form Of Engagement Activity	A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Media (as a channel to the public)
Results and Impact	26 February Siemens released a video of Alwyn Jones, Siemens UK & Ireland Head of Pharmaceutical & Life Sciences, in conversation with CMAC's Industry Director Craig Johnston
Year(s) Of Engagement Activity	2018
URL	https://www.youtube.com/watch?v=kbzSgHFn_w4&__prclt=DZb25HTl


Description	Strathclyde in Medicines Manufacturing Innovation Centre - press release
Form Of Engagement Activity	A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Media (as a channel to the public)
Results and Impact	15 June Strathclyde in Medicines Manufacturing Innovation Centre Full press release link below.
Year(s) Of Engagement Activity	2018
URL	https://www.strath.ac.uk/whystrathclyde/news/strathclydeinmedicinesmanufacturinginnovationcentre/


Description	Talk by Dr Jag Srai (CoI): Building Back Better: harnessing technology to create new products, markets and business models
Form Of Engagement Activity	A talk or presentation
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Postgraduate students
Results and Impact	25th International Manufacturing Symposium (Online) - https://cimsymposium.eng.cam.ac.uk/2021programme. Talk: Building Back Better: harnessing technology to create new products, markets and business models. Speakers: Nitin Joglekar (Boston University, USA); Geoff Parker (Dartmouth/MIT, USA); Jag Srai (Cambridge University)
Year(s) Of Engagement Activity	2021
URL	https://cimsymposium.eng.cam.ac.uk/2021programme


Description	UK Manufacturing Outlook 2022
Form Of Engagement Activity	A magazine, newsletter or online publication
Part Of Official Scheme?	No
Geographic Reach	National
Primary Audience	Media (as a channel to the public)
Results and Impact	CMAC Future Manufacturing Research Hub is featured in UK Manufacturing Outlook 2022. Tweet from UK Manufacturing Outlook 2022: @ukmfgoutlook·Jun 9, 2022: UK's #Medicines #manufacturing exports >£25bn, has the highest GVA of any sector (£8.5bn) & invests >£4bn pa on R&D. The CMAC Future Manufacturing Research Hub is developing more efficient, responsive & resilient processes for a market projected to grow 3-6%pa to £1.2tr by 2025.
Year(s) Of Engagement Activity	2022
URL	https://uk-mo.com/technologies/transforming-medicines-manufacturing


Description	Video of talk "Supercritical CO2 Drying End-Point by Using SIFT-MS Analysis"
Form Of Engagement Activity	A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme?	No
Geographic Reach	National
Primary Audience	Public/other audiences
Results and Impact	Video of talk "Supercritical CO2 Drying End-Point by Using SIFT-MS Analysis" by CMAC PhD Georgia Sanxaridou (Dr Chris Price's group at University of Strathclyde) at The SIFT-MS Interest Group Meeting 2019. Here is the link https://www.youtube.com/watch?v=XoOMgv1unQU&list=PL3J3TYiNeMFpBFzXYoY5JcFItH93rvflh?dex=4&t=0s
Year(s) Of Engagement Activity	2019
URL	https://www.youtube.com/watch?v=XoOMgv1unQU&list=PL3J3TYiNeMFpBFzXYoY5JcFItH93rvflh&index=4&t=0s


Description	Visit by MP Carol Monaghan
Form Of Engagement Activity	Participation in an open day or visit at my research institution
Part Of Official Scheme?	No
Geographic Reach	Local
Primary Audience	Policymakers/politicians
Results and Impact	CMAC hosted MP Carol Monaghan on 5th October 2022 (@CMonaghanSNP) and showcased all the innovative medicines manufacturing research being carried out by CMAC here in Glasgow.
Year(s) Of Engagement Activity	2022


Description	Visit by Parliamentary Under Secretary of State (Minister for Small Business, Consumers and Labour Markets)
Form Of Engagement Activity	Participation in an open day or visit at my research institution
Part Of Official Scheme?	No
Geographic Reach	Local
Primary Audience	Policymakers/politicians
Results and Impact	17/02/2022: CMAC host UK were thrilled to host Parliamentary Under Secretary of State (Minister for Small Business, Consumers and Labour Markets), @scullyp this week and provide a tour of our facilities highlighting #CMACs vision to transform #medicines development, manufacture and supply.
Year(s) Of Engagement Activity	2022


Description	Visit by UK Science and Technology Select Committee
Form Of Engagement Activity	Participation in an open day or visit at my research institution
Part Of Official Scheme?	No
Geographic Reach	Local
Primary Audience	Policymakers/politicians
Results and Impact	11/02/2022: CMAC were delighted to host the UK Science and Technology Select Committee this week! We were excited to provide its members with a guided tour of our #facilities and show how #CMAC are helping tackle major UK and global challenges in #medicinesmanufacturing. #researchexcellence
Year(s) Of Engagement Activity	2022


Description	Webinar on the #FutureOfWork in Medicines #Manufacturing
Form Of Engagement Activity	A talk or presentation
Part Of Official Scheme?	No
Geographic Reach	National
Primary Audience	Industry/Business
Results and Impact	@ESRC @InterActNetw0rk collaborated with CMAC to host a webinar on the #FutureOfWork in Medicines #Manufacturing, Thursday 12 January, 2023. Traget audience members: people manager or workplace stakeholder in the sector.
Year(s) Of Engagement Activity	2023
URL	https://linkedin.com/pulse/digital-medicines-manufacturing-future-work-webinar-lindsay-mcipd-/


Description	Webinar: From particles to drug product performance and stability
Form Of Engagement Activity	Participation in an activity, workshop or similar
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Industry/Business
Results and Impact	Webinar hosted by industry partner, Malvern Panalytical. Showcasing our medicines manufacturing related activities, the benefits of partnership and garnering opinion of our extended networks
Year(s) Of Engagement Activity	2023
URL	https://cmac.ac.uk/resource-database/drug-performance-and-stability-webinar


Description	Webinar: Time to go digital: digitalisation and AI in pharmaceutical R&D
Form Of Engagement Activity	Participation in an activity, workshop or similar
Part Of Official Scheme?	No
Geographic Reach	International
Primary Audience	Industry/Business
Results and Impact	Webinar hosted by industry partner, Malvern Panalytical. Showcasing our data related activities, the benefits of partnership and garnering opinion of our extended networks
Year(s) Of Engagement Activity	2023
URL	https://cmac.ac.uk/events-database/future-of-work-webinar-cp9c2

Abstract

Planned Impact

Organisations

People

ORCID iD

Publications